1
|
Muntner P, Ghazi L, Jones J, Dhalwani N, Poudel B, Wen Y, Chen L, Wang Z, Bittner V, Kalich B, Farkouh ME, Woodward M, Colantonio LD, Rosenson RS. Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings. Adv Ther 2024:10.1007/s12325-024-02868-z. [PMID: 38691317 DOI: 10.1007/s12325-024-02868-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Accepted: 04/04/2024] [Indexed: 05/03/2024]
Abstract
INTRODUCTION The cardiovascular disease risk reduction benefits of proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibodies (PCSK9i mAb) and ezetimibe are dependent on remaining on treatment and being persistent and adherent. We estimated the percentage of patients on therapy, persistent and adherent at 182 and 365 days among US adults with health insurance who initiated a PCSK9i mAb (n = 16,588) or ezetimibe (n = 83,086) between July 2015 and December 2019. METHODS Using pharmacy fill claims, being on therapy was defined as having a day of medication supply in the last 60 of 182 and 365 days following treatment initiation, being persistent was defined as not having a gap of 60 days or more between the last day of supply from one prescription fill and the next fill, and being adherent was defined by having medication available to take on ≥ 80% of the 182 and 365 days following treatment initiation. We estimated multivariable-adjusted risk ratios for being persistent and adherent comparing patients initiating PCSK9i mAb versus ezetimibe using Poisson regression. RESULTS At 182 days following initiation, 80% and 68% were on therapy and 76% and 64% were persistent among patients who initiated a PCSK9i mAb and ezetimibe, respectively. Among patients who were on therapy and persistent at 182 days following initiation, 88% and 81% of those who initiated a PCSK9i mAb and ezetimibe, respectively, were on therapy at 365 days. Among those on therapy and persistent at 182 days following initiation, being persistent and being adherent at 365 days were each more common among PCSK9i mAb versus ezetimibe initiators (persistent: 82% versus 76%, multivariable-adjusted risk ratio 1.07; 95% confidence interval [CI] 1.06-1.08; adherent: 74% versus 71%, multivariable-adjusted risk ratio 1.02; 95% CI 1.01-1.03). CONCLUSIONS These data suggest approaches to increase persistence and adherence to PCSK9i mAb and ezetimibe should be implemented prior to or within 182 days following treatment initiation.
Collapse
Affiliation(s)
- Paul Muntner
- Department of Epidemiology, University of Alabama at Birmingham, 1665 University Boulevard, Birmingham, AL, 35294, USA
| | - Lama Ghazi
- Department of Epidemiology, University of Alabama at Birmingham, 1665 University Boulevard, Birmingham, AL, 35294, USA.
| | - Jenna Jones
- Center for Observational Research, Amgen Inc., Thousand Oaks, CA, USA
| | - Nafeesa Dhalwani
- Center for Observational Research, Amgen Inc., Thousand Oaks, CA, USA
| | - Bharat Poudel
- Department of Epidemiology, University of Alabama at Birmingham, 1665 University Boulevard, Birmingham, AL, 35294, USA
| | - Ying Wen
- Department of Epidemiology, University of Alabama at Birmingham, 1665 University Boulevard, Birmingham, AL, 35294, USA
| | - Ligong Chen
- Department of Epidemiology, University of Alabama at Birmingham, 1665 University Boulevard, Birmingham, AL, 35294, USA
| | - Zhixin Wang
- Department of Epidemiology, University of Alabama at Birmingham, 1665 University Boulevard, Birmingham, AL, 35294, USA
| | - Vera Bittner
- Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | | | - Michael E Farkouh
- Department of Medicine, Cedar-Sinai School of Medicine, Los Angeles, CA, USA
| | - Mark Woodward
- The George Institute for Global Health, School of Public Health, Imperial College London, London, UK
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| | - Lisandro D Colantonio
- Department of Epidemiology, University of Alabama at Birmingham, 1665 University Boulevard, Birmingham, AL, 35294, USA
| | - Robert S Rosenson
- Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
| |
Collapse
|
2
|
Peikert A, Claggett BL, Udell JA, Joseph J, Hegde SM, Kim K, Mao L, Wang T, Havighurst TC, Farkouh ME, Bhatt DL, Tattersall MC, Cooper LS, Solomon SD, Vardeny O. Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial. JAMA Cardiol 2024:2817470. [PMID: 38583091 PMCID: PMC11000133 DOI: 10.1001/jamacardio.2024.0468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Accepted: 02/13/2024] [Indexed: 04/08/2024]
Abstract
Importance High-dose trivalent compared with standard-dose quadrivalent influenza vaccine did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations in patients with high-risk cardiovascular disease in the INVESTED trial. Whether humoral immune response to influenza vaccine is associated with clinical outcomes is unknown. Objective To examine the antibody response to high-dose trivalent compared with standard-dose quadrivalent inactivated influenza vaccine and its associations with clinical outcomes. Design, Setting, and Participants This secondary analysis is a prespecified analysis of the immune response substudy of the randomized, double-blind, active-controlled INVESTED trial, which was conducted at 157 sites in the United States and Canada over 3 influenza seasons between September 2016 and January 2019. Antibody titers were determined by hemagglutination inhibition assays at randomization and 4 weeks during the 2017-2018 and 2018-2019 seasons. Eligibility criteria included recent acute myocardial infarction or heart failure hospitalization and at least 1 additional risk factor. Data were analyzed from February 2023 to June 2023. Main Outcomes and Measures Mean antibody titer change, seroprotection (antibody titer level ≥1:40) and seroconversion (≥4-fold increase in titer) at 4 weeks, and the association between seroconversion status and the risk for adverse clinical outcomes. Interventions High-dose trivalent or standard-dose quadrivalent inactivated influenza vaccine, with revaccination up to 3 seasons. Results Antibody data were available for 658 of 5260 randomized participants (12.5%; mean [SD] age, 66.2 [11.4] years; 507 male [77.1%], 151 female [22.9%]; 348 with heart failure [52.9%]). High-dose vaccine was associated with an increased magnitude in antibody titers for A/H1N1, A/H3N2, and B-type antigens compared with standard dose. More than 92% of all participants achieved seroprotection for each of the contained antigens, while seroconversion rates were higher in participants who received high-dose vaccine. Seroconversion for any antigen was not associated with the risk for cardiopulmonary hospitalizations or all-cause mortality (hazard ratio, 1.09; 95% CI, 0.79-1.53; P = .59), irrespective of randomized treatment (P = .38 for interaction). Conclusions and Relevance High-dose vaccine elicited a more robust humoral response in patients with heart failure or prior myocardial infarction enrolled in the INVESTED trial, with no association between seroconversion status and the risk for cardiopulmonary hospitalizations or all-cause mortality. Vaccination to prevent influenza remains critical in high-risk populations. Trial Registration ClinicalTrials.gov Identifier: NCT02787044.
Collapse
Affiliation(s)
- Alexander Peikert
- Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
- University Heart Center Graz, Department of Cardiology, Medical University of Graz, Graz, Austria
| | - Brian L. Claggett
- Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Jacob A. Udell
- Peter Munk Cardiac Centre, University Health Network and Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Jacob Joseph
- Department of Medicine, VA Providence Healthcare System and Brown University, Providence, Rhode Island
| | - Sheila M. Hegde
- Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - KyungMann Kim
- Department of Biostatistics and Medical Informatics, University of Wisconsin–Madison, Madison
| | - Lu Mao
- Department of Biostatistics and Medical Informatics, University of Wisconsin–Madison, Madison
| | - Tuo Wang
- Department of Biostatistics and Medical Informatics, University of Wisconsin–Madison, Madison
| | - Thomas C. Havighurst
- Department of Biostatistics and Medical Informatics, University of Wisconsin–Madison, Madison
| | | | - Deepak L. Bhatt
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York
| | - Matthew C. Tattersall
- Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin–Madison, Madison
| | | | - Scott D. Solomon
- Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Orly Vardeny
- Department of Medicine, University of Minnesota, Minneapolis VA Health Care System, Minneapolis
| |
Collapse
|
3
|
Gaudino M, Audisio K, Hueb WA, Stone GW, Farkouh ME, Di Franco A, Rahouma M, Serruys PW, Bhatt DL, Biondi Zoccai G, Yusuf S, Girardi LN, Fremes SE, Ruel M, Redfors B. Coronary artery bypass grafting versus medical therapy in patients with stable coronary artery disease: An individual patient data pooled meta-analysis of randomized trials. J Thorac Cardiovasc Surg 2024; 167:1022-1032.e14. [PMID: 35821087 DOI: 10.1016/j.jtcvs.2022.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Revised: 05/16/2022] [Accepted: 06/01/2022] [Indexed: 11/21/2022]
Abstract
OBJECTIVES It is unclear whether coronary artery bypass grafting (CABG) improves survival compared with medical therapy (MT) in patients with stable coronary artery disease (CAD). The aim of this analysis was to perform an individual-patient data-pooled meta-analysis of contemporary randomized controlled trials that compared CABG and MT in patients with stable CAD. METHODS A systematic search was performed in January 2021 to identify randomized controlled trials enrolling adult patients with stable CAD, randomized to CABG or MT. Only trials using at least aspirin, beta-blockers, and statins in the MT arm were included. Individual patient data were obtained from all eligible studies and pooled. The primary outcome was all-cause mortality. RESULTS Four trials involving 2523 patients (1261 CABG; 1262 MT) were included with a median follow-up of 5.6 (4.0-9.2) years. CABG was associated with increased risk of all-cause mortality within 30 days (hazard ratio [HR], 4.81; 95% confidence interval [CI], 1.95-11.83) but subsequent reduction in the long-term risk of death (HR, 0.79; 95% CI, 0.69-0.89). As such, the cumulative 10-year mortality rate was lower in patients treated with CABG compared with MT (45.1% vs 51.7%, respectively; odds ratio, 0.70; 95% CI, 0.58-0.85). Age and race were significant treatment effect modifier (interaction P = .003 for both). CONCLUSIONS In patients with stable CAD, initial allocation to CABG was associated with greater periprocedural risk of death but improved long-term survival compared with MT. The survival advantage for CABG became significant after the fourth postoperative year and was particularly pronounced in younger and non-White patients.
Collapse
Affiliation(s)
- Mario Gaudino
- Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY.
| | - Katia Audisio
- Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY
| | - Whady A Hueb
- Heart Institute of the University of São Paulo, São Paulo, Brazil
| | - Gregg W Stone
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY
| | - Michael E Farkouh
- Peter Munk Cardiac Centre and the Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada
| | - Antonino Di Franco
- Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY
| | - Mohamed Rahouma
- Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY
| | - Patrick W Serruys
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Deepak L Bhatt
- Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, Mass
| | - Giuseppe Biondi Zoccai
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; Mediterranea Cardiocentro, Napoli, Italy
| | - Salim Yusuf
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Leonard N Girardi
- Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY
| | - Stephen E Fremes
- Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | - Marc Ruel
- University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada
| | - Bjorn Redfors
- Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Clinical Trials Center, Cardiovascular Research Foundation, New York, NY; NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY
| |
Collapse
|
4
|
Sud M, Sivaswamy A, Austin PC, Anderson TJ, Naimark DMJ, Farkouh ME, Lee DS, Roifman I, Thanassoulis G, Tu K, Udell JA, Wijeysundera HC, Ko DT. Development and Validation of the CANHEART Population-Based Laboratory Prediction Models for Atherosclerotic Cardiovascular Disease. Ann Intern Med 2023; 176:1638-1647. [PMID: 38079638 DOI: 10.7326/m23-1345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2023] Open
Abstract
BACKGROUND Prediction of atherosclerotic cardiovascular disease (ASCVD) in primary prevention assessments exclusively with laboratory results may facilitate automated risk reporting and improve uptake of preventive therapies. OBJECTIVE To develop and validate sex-specific prediction models for ASCVD using age and routine laboratory tests and compare their performance with that of the pooled cohort equations (PCEs). DESIGN Derivation and validation of the CANHEART (Cardiovascular Health in Ambulatory Care Research Team) Lab Models. SETTING Population-based cohort study in Ontario, Canada. PARTICIPANTS A derivation and internal validation cohort of adults aged 40 to 75 years without cardiovascular disease from April 2009 to December 2015; an external validation cohort of primary care patients from January 2010 to December 2014. MEASUREMENTS Age and laboratory predictors measured in the outpatient setting included serum total cholesterol, high-density lipoprotein cholesterol, triglycerides, hemoglobin, mean corpuscular volume, platelets, leukocytes, estimated glomerular filtration rate, and glucose. The ASCVD outcomes were defined as myocardial infarction, stroke, and death from ischemic heart or cerebrovascular disease within 5 years. RESULTS Sex-specific models were developed and internally validated in 2 160 497 women and 1 833 147 men. They were well calibrated, with relative differences less than 1% between mean predicted and observed risk for both sexes. The c-statistic was 0.77 in women and 0.71 in men. External validation in 31 697 primary care patients showed a relative difference less than 14% and an absolute difference less than 0.3 percentage points in mean predicted and observed risks for both sexes. The c-statistics for the laboratory models were 0.72 for both sexes and were not statistically significantly different from those for the PCEs in women (change in c-statistic, -0.01 [95% CI, -0.03 to 0.01]) or men (change in c-statistic, -0.01 [CI, -0.04 to 0.02]). LIMITATION Medication use was not available at the population level. CONCLUSION The CANHEART Lab Models predict ASCVD with similar accuracy to more complex models, such as the PCEs. PRIMARY FUNDING SOURCE Canadian Institutes of Health Research.
Collapse
Affiliation(s)
- Maneesh Sud
- Schulich Heart Program, Sunnybrook Health Sciences Centre, University of Toronto; Institute of Health Policy, Management and Evaluation, University of Toronto; ICES; and Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (M.S., I.R., H.C.W., D.T.K.)
| | | | - Peter C Austin
- Institute of Health Policy, Management and Evaluation, University of Toronto, and ICES, Toronto, Ontario, Canada (P.C.A.)
| | - Todd J Anderson
- Libin Cardiovascular Institute and Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (T.J.A.)
| | - David M J Naimark
- Institute of Health Policy, Management and Evaluation, University of Toronto; ICES; and Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (D.M.J.N.)
| | - Michael E Farkouh
- Academic Affairs, Cedars-Sinai Health System, Los Angeles, California (M.E.F.)
| | - Douglas S Lee
- Institute of Health Policy, Management and Evaluation, University of Toronto; ICES; Temerty Faculty of Medicine, University of Toronto; Peter Munk Cardiac Centre, University Health Network, University of Toronto; and Ted Rogers Centre for Heart Research, Toronto, Ontario, Canada (D.S.L.)
| | - Idan Roifman
- Schulich Heart Program, Sunnybrook Health Sciences Centre, University of Toronto; Institute of Health Policy, Management and Evaluation, University of Toronto; ICES; and Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (M.S., I.R., H.C.W., D.T.K.)
| | - George Thanassoulis
- Department of Medicine, McGill University, and Preventive and Genomic Cardiology, McGill University Health Centre, Montreal, Quebec, Canada (G.T.)
| | - Karen Tu
- Toronto Western Family Health Team, University Health Network, North York General Hospital, and Department of Family and Community Medicine, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada (K.T.)
| | - Jacob A Udell
- Institute of Health Policy, Management and Evaluation, University of Toronto; ICES; Temerty Faculty of Medicine, University of Toronto; Peter Munk Cardiac Centre, University Health Network, University of Toronto; and Women's College Hospital, University of Toronto, Toronto, Ontario, Canada (J.A.U.)
| | - Harindra C Wijeysundera
- Schulich Heart Program, Sunnybrook Health Sciences Centre, University of Toronto; Institute of Health Policy, Management and Evaluation, University of Toronto; ICES; and Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (M.S., I.R., H.C.W., D.T.K.)
| | - Dennis T Ko
- Schulich Heart Program, Sunnybrook Health Sciences Centre, University of Toronto; Institute of Health Policy, Management and Evaluation, University of Toronto; ICES; and Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (M.S., I.R., H.C.W., D.T.K.)
| |
Collapse
|
5
|
Godoy LC, Ko DT, Farkouh ME, Shah BR, Austin PC. Dealing With Nonproportional Hazards in Coronary Revascularisation Studies. Can J Cardiol 2023; 39:1651-1660. [PMID: 37468120 DOI: 10.1016/j.cjca.2023.07.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 07/12/2023] [Accepted: 07/13/2023] [Indexed: 07/21/2023] Open
Abstract
The Cox proportional hazards model is one of the most popular statistical tools to model time to event outcomes without the need for specifying the hazards or survival time distributions. The Cox model requires that the ratio of the hazards of the occurrence of the outcome for any 2 individuals remains constant during the entire follow-up. Studies comparing coronary revascularisation strategies, however, might be prone to violations of proportionality by the crossing of the hazard functions over time. Early increases in the risk of cardiovascular outcomes are commonly observed when comparing coronary artery bypass grafting vs percutaneous coronary intervention, whereas decreased risk might be observed later during the follow-up. The same is valid for comparisons between invasive vs conservative coronary revascularisation strategies. In these situations, the statistical power of the Cox model is reduced, and hazard ratios might not be an informative summary measure of treatment effect. In this article, we discuss methods to identify and account for nonproportionality. We illustrate the use of these methods in a case study based on reconstructed data from a coronary revascularisation clinical trial. And finally, we review the cardiovascular literature to estimate how the proportionality assumption has been reported in coronary revascularisation studies recently.
Collapse
Affiliation(s)
- Lucas C Godoy
- Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | - Dennis T Ko
- ICES, Toronto, Ontario, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Michael E Farkouh
- Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada; Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Baiju R Shah
- ICES, Toronto, Ontario, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Peter C Austin
- ICES, Toronto, Ontario, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
| |
Collapse
|
6
|
Godoy LC, Farkouh ME, Ko DT. Reply: Beta-Blockers in Stable Ischemic Heart Disease. J Am Coll Cardiol 2023; 82:e169. [PMID: 37879789 DOI: 10.1016/j.jacc.2023.08.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Accepted: 08/07/2023] [Indexed: 10/27/2023]
Affiliation(s)
- Lucas C Godoy
- Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada; Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, Brazil
| | - Michael E Farkouh
- Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada; Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Dennis T Ko
- ICES, Toronto, Ontario, Canada; Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada..
| |
Collapse
|
7
|
Farkouh ME, Mathew V. Another Piece in the Diabetes and Multivessel Coronary Disease Puzzle. JACC Cardiovasc Interv 2023; 16:2423-2425. [PMID: 37821188 DOI: 10.1016/j.jcin.2023.08.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Accepted: 08/29/2023] [Indexed: 10/13/2023]
Affiliation(s)
- Michael E Farkouh
- Academic Affairs, Cedars-Sinai Health System, Los Angeles, California, USA.
| | - Verghese Mathew
- Swedish Hospital NorthShore University Health System, Chicago, Illinois, USA
| |
Collapse
|
8
|
Hegde SM, Claggett BL, Udell JA, Kim K, Joseph J, Farkouh ME, Peikert A, Bhatt AS, Tattersall MC, Bhatt DL, Cooper LS, Solomon SD, Vardeny O. Temporal Association Among Influenza-Like Illness, Cardiovascular Events, and Vaccine Dose in Patients With High-Risk Cardiovascular Disease: Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open 2023; 6:e2331284. [PMID: 37707817 PMCID: PMC10502520 DOI: 10.1001/jamanetworkopen.2023.31284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Accepted: 07/22/2023] [Indexed: 09/15/2023] Open
Abstract
Importance Influenza-like illness (ILI) activity has been associated with increased risk of cardiopulmonary (CP) events during the influenza season. High-dose trivalent influenza vaccine was not superior to standard-dose quadrivalent vaccine for reducing these events in patients with high-risk cardiovascular (CV) disease in the Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED) trial. Objective To evaluate whether high-dose trivalent influenza vaccination is associated with benefit over standard-dose quadrivalent vaccination in reducing CP events during periods of high, local influenza activity. Design, Setting, and Participants This study was a prespecified secondary analysis of INVESTED, a multicenter, double-blind, active comparator randomized clinical trial conducted over 3 consecutive influenza seasons from September 2016 to July 2019. Follow-up was completed in July 2019, and data were analyzed from September 21, 2016, to July 31, 2019. Weekly Centers for Disease Control and Prevention (CDC)-reported, state-level ILI activity was ascertained to assess the weekly odds of the primary outcome. The study population included 3094 patients with high-risk CV disease from participating centers in the US. Intervention Participants were randomized to high-dose trivalent or standard-dose quadrivalent influenza vaccine and revaccinated for up to 3 seasons. Main Outcomes and Measures The primary outcome was the time to composite of all-cause death or CP hospitalization within each season. Additional measures included weekly CDC-reported ILI activity data by state. Results Among 3094 participants (mean [SD] age, 65 [12] years; 2309 male [75%]), we analyzed 129 285 person-weeks of enrollment, including 1396 composite primary outcome events (1278 CP hospitalization, 118 deaths). A 1% ILI increase in the prior week was associated with an increased risk in the primary outcome (odds ratio [OR], 1.14; 95% CI, 1.07-1.21; P < .001), CP hospitalization (OR, 1.13; 95% CI, 1.06-1.21; P < .001), and CV hospitalization (OR, 1.12; 95% CI, 1.04-1.19; P = .001), after adjusting for state, demographic characteristics, enrollment strata, and CV risk factors. Increased ILI activity was not associated with all-cause death (OR, 1.00; 95% CI, 0.88-1.13; P > .99). High-dose compared with standard-dose vaccine did not significantly reduce the primary outcome, even when the analysis was restricted to weeks of high ILI activity (OR, 0.88; 95% CI, 0.65-1.20; P = .43). Traditionally warmer months in the US were associated with lower CV risk independent of local ILI activity. Conclusions and Relevance In this secondary analysis of a randomized clinical trial, ILI activity was temporally associated with increased CP events in patients with high-risk CV disease, and a higher influenza vaccine dose did not significantly reduce temporal CV risk. Other seasonal factors may play a role in the coincident high rates of ILI and CV events. Trial Registration ClinicalTrials.gov Identifier: NCT02787044.
Collapse
Affiliation(s)
- Sheila M. Hegde
- Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Brian L. Claggett
- Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Jacob A. Udell
- Women’s College Hospital and Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada
| | - KyungMann Kim
- Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison
| | - Jacob Joseph
- Brown University, The Warren Alpert Medical School, Providence, Rhode Island
| | - Michael E. Farkouh
- Women’s College Hospital and Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada
| | - Alexander Peikert
- Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Ankeet S. Bhatt
- Kaiser Permanente Division of Research, Northern California, Oakland
| | | | - Deepak L. Bhatt
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, New York, New York
| | - Lawton S. Cooper
- National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, Maryland
| | - Scott D. Solomon
- Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | - Orly Vardeny
- Department of Medicine, University of Minnesota, Minneapolis
- VA Minneapolis Health Care System, US Department of Veterans Affairs, Minneapolis, Minnesota
| |
Collapse
|
9
|
Stone GW, Farkouh ME, Fuster V. Reply: Anticoagulation in Noncritically Ill Patients Hospitalized With COVID-19. J Am Coll Cardiol 2023; 82:e59-e60. [PMID: 37558380 DOI: 10.1016/j.jacc.2023.04.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Accepted: 04/11/2023] [Indexed: 08/11/2023]
|
10
|
Fremes SE, Marquis-Gravel G, Gaudino MFL, Jolicoeur EM, Bédard S, Masterson Creber R, Ruel M, Vervoort D, Wijeysundera HC, Farkouh ME, Rouleau JL. STICH3C: Rationale and Study Protocol. Circ Cardiovasc Interv 2023; 16:e012527. [PMID: 37582169 DOI: 10.1161/circinterventions.122.012527] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/03/2022] [Accepted: 07/03/2023] [Indexed: 08/17/2023]
Abstract
BACKGROUND Coronary artery bypass grafting (CABG) is the recommended mode of revascularization in patients with ischemic left ventricular dysfunction (iLVSD) and multivessel disease. However, contemporary percutaneous coronary intervention (PCI) outcomes have improved with the integration of novel technologies and refinement of revascularization strategies, and PCI is often used in clinical practice in this population. There is a lack of evidence from randomized trials comparing contemporary state-of-the-art PCI versus CABG for the treatment of iLVSD and multivessel disease. This was the impetus for the STICH3C trial (Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy), described here. METHODS The STICH3C trial is a prospective, unblinded, international, multicenter trial with an expected sample size of 754 participants from ≈45 centers. Patients with multivessel/left main coronary artery disease and iLVSD with left ventricular ejection fraction ≤40% considered by the local Heart Team appropriate for and amenable to revascularization by both modes of revascularization will be randomized in a 1:1 ratio to state-of-the-art PCI or CABG. RESULTS The primary end point is the composite of death from any cause, stroke, spontaneous myocardial infarction, urgent repeat revascularization, or heart failure readmission, summarized as a time-to-event outcome. The key hierarchical end point is time to death and frequency of hospitalizations for heart failure. The key safety outcome is a composite of major adverse events. Disease-specific quality-of-life and health economics measures will be compared between groups. Participants will be followed for a median of 5 years, with a minimum follow-up of 4 years. CONCLUSIONS STICH3C will directly inform patients, clinicians, and international practice guidelines about the efficacy and safety of CABG versus PCI in patients with iLVSD. The results will provide novel and broad evidence, including clinical events, health status, and economic assessments, to guide care for patients with iLVSD and severe coronary artery disease. REGISTRATION URL: https://clinicaltrials.gov/; Unique identifier: NCT05427370.
Collapse
Affiliation(s)
- Stephen E Fremes
- Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada (S.E.F., D.V., H.C.W.)
| | | | - Mario F L Gaudino
- Department of Cardiothoracic Surgery (M.F.L.G.), Weill Cornell Medicine, New York City, NY
| | - E Marc Jolicoeur
- Department of Cardiothoracic Surgery (M.F.L.G.), Weill Cornell Medicine, New York City, NY
| | - Sylvain Bédard
- Centre d'excellence sur le partenariat avec les patients et le public, Montreal, Quebec, Canada (S.B.)
| | | | - Marc Ruel
- Division of Cardiac Surgery, University of Ottawa Heart Institute, Ontario, Canada (M.R.)
| | - Dominique Vervoort
- Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada (S.E.F., D.V., H.C.W.)
| | - Harindra C Wijeysundera
- Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada (S.E.F., D.V., H.C.W.)
| | - Michael E Farkouh
- Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, Ontario, Canada (M.E.F.)
| | - Jean-Lucien Rouleau
- Montreal Heart Institute, University of Montreal, Quebec, Canada (G.M.-G., E.M.J., J.-L.R.)
| |
Collapse
|
11
|
Colantonio LD, Goonewardena SN, Wang Z, Jackson EA, Farkouh ME, Li M, Malick W, Kent ST, López JAG, Muntner P, Bittner V, Rosenson RS. Incident CHD and ischemic stroke associated with lipoprotein(a) by levels of Factor VIII and inflammation. J Clin Lipidol 2023; 17:529-537. [PMID: 37331900 DOI: 10.1016/j.jacl.2023.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 05/16/2023] [Accepted: 06/06/2023] [Indexed: 06/20/2023]
Abstract
BACKGROUND Inflammation and coagulation may contribute to the increased risk for atherosclerotic cardiovascular disease (ASCVD) associated with high lipoprotein(a). The association of lipoprotein(a) with ASCVD is stronger in individuals with high versus low high-sensitivity C-reactive protein (hs-CRP), a marker of inflammation. OBJECTIVES Determine the association of lipoprotein(a) with incident ASCVD by levels of coagulation Factor VIII controlling for hs-CRP. METHODS We analyzed data from 6,495 men and women 45 to 84 years of age in the Multi-Ethnic Study of Atherosclerosis (MESA) without prevalent ASCVD at baseline (2000-2002). Lipoprotein(a) mass concentration, Factor VIII coagulant activity, and hs-CRP were measured at baseline and categorized as high or low (≥75th or <75th percentile of the distribution). Participants were followed for incident coronary heart disease (CHD) and ischemic stroke through 2015. RESULTS Over a median follow-up of 13.9 years, there were 390 CHD and 247 ischemic stroke events. The hazard ratio (95%CI) for CHD associated with high lipoprotein(a) (≥40.1 versus <40.1 mg/dL) including adjustment for hs-CRP among participants with low and high Factor VIII was 1.07 (0.80-1.44) and 2.00 (1.33-3.01), respectively (p-value for interaction 0.016). The hazard ratio (95%CI) for CHD associated with high lipoprotein(a) including adjustment for Factor VIII was 1.16 (0.87-1.54) and 2.00 (1.29-3.09) among participants with low and high hs-CRP, respectively (p-value for interaction 0.042). Lp(a) was not associated with ischemic stroke regardless of Factor VIII or hs-CRP levels. CONCLUSION High lipoprotein(a) is a risk factor for CHD in adults with high levels of hemostatic or inflammatory markers.
Collapse
Affiliation(s)
- Lisandro D Colantonio
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA (Drs Colantonio, Wang, Li, Muntner, Rosenson).
| | - Sascha N Goonewardena
- Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA (Dr Goonewardena)
| | - Zhixin Wang
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA (Drs Colantonio, Wang, Li, Muntner, Rosenson)
| | - Elizabeth A Jackson
- Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA (Drs Jackson, Bittner)
| | - Michael E Farkouh
- Peter Munk Cardiac Centre, University of Toronto and Heart and Stroke Richard Lewar Centre of Excellence, Toronto, ON, Canada (Dr Farkouh)
| | - Mei Li
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA (Drs Colantonio, Wang, Li, Muntner, Rosenson)
| | - Waqas Malick
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA (Drs Malick, Rosenson)
| | - Shia T Kent
- Center for Observational Research, Amgen Inc., Thousand Oaks, CA, USA (Dr Kent)
| | | | - Paul Muntner
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA (Drs Colantonio, Wang, Li, Muntner, Rosenson)
| | - Vera Bittner
- Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA (Drs Jackson, Bittner)
| | - Robert S Rosenson
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA (Drs Malick, Rosenson)
| |
Collapse
|
12
|
Godoy LC, Farkouh ME, Austin PC, Shah BR, Qiu F, Jackevicius CA, Wijeysundera HC, Krumholz HM, Ko DT. Association of Beta-Blocker Therapy With Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease. J Am Coll Cardiol 2023; 81:2299-2311. [PMID: 37316110 DOI: 10.1016/j.jacc.2023.04.021] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Accepted: 04/14/2023] [Indexed: 06/16/2023]
Abstract
BACKGROUND Previous studies have failed to show a cardioprotective benefit of beta-blockers in patients with stable coronary artery disease (CAD). OBJECTIVES This study sought to determine the association between beta-blockers and cardiovascular events in patients with stable CAD using a new user design. METHODS All patients aged >66 years undergoing elective coronary angiography in Ontario, Canada, from 2009 to 2019 with diagnosed obstructive CAD were included. Exclusion criteria included heart failure or a recent myocardial infarction, as well as having a beta-blocker prescription claim in the previous year. Beta-blocker use was defined as having at least 1 beta-blocker prescription claim in the 90 days preceding or after the index coronary angiography. The main outcome was a composite of all-cause mortality and hospitalization for heart failure or myocardial infarction. Inverse probability of treatment weighting using the propensity score was used to account for confounding. RESULTS This study included 28,039 patients (mean age: 73.0 ± 5.6 years; 66.2% male), and 12,695 of those (45.3%) were newly prescribed beta-blockers. The 5-year risks of the primary outcome were 14.3% in the beta-blocker group and 16.1% in the no beta-blocker group (absolute risk reduction: -1.8%; 95% CI: -2.8 to -0.8; HR: 0.92; 95% CI: 0.86-0.98; P = 0.006). This result was driven by reductions in myocardial infarction hospitalization (cause-specific HR: 0.87; 95% CI: 0.77-0.99; P = 0.031), whereas no differences were observed in all-cause death or heart failure hospitalization. CONCLUSIONS In patients with angiographically documented stable CAD without heart failure or a recent myocardial infarction, beta-blockers were associated with a small but significant reduction in cardiovascular events at 5 years.
Collapse
Affiliation(s)
- Lucas C Godoy
- Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, Ontario, Canada; Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
| | - Michael E Farkouh
- Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada; Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Peter C Austin
- ICES, Toronto, Ontario, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, Ontario, Canada
| | - Baiju R Shah
- ICES, Toronto, Ontario, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | | | - Cynthia A Jackevicius
- ICES, Toronto, Ontario, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, Ontario, Canada; Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA; Western University of Health Services, Pomona, California, USA
| | - Harindra C Wijeysundera
- ICES, Toronto, Ontario, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Harlan M Krumholz
- Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut, USA; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA; Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA
| | - Dennis T Ko
- ICES, Toronto, Ontario, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
| |
Collapse
|
13
|
Godoy LC, Farkouh ME, Zarychanski R, Lawler PR. The Impact of COVID-19 Research on the Development of Scalable Frameworks for Efficient Clinical Trials in Cardiovascular Medicine. Can J Cardiol 2023; 39:764-766. [PMID: 36931622 PMCID: PMC10015822 DOI: 10.1016/j.cjca.2023.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Revised: 03/08/2023] [Accepted: 03/09/2023] [Indexed: 03/17/2023] Open
Affiliation(s)
- Lucas C Godoy
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada; Clinical Trials and Translation Unit, Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada; Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | - Michael E Farkouh
- Clinical Trials and Translation Unit, Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada; Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Ryan Zarychanski
- University of Manitoba, Winnipeg, Manitoba, Canada; CancerCare Manitoba, Winnipeg, Manitoba, Canada
| | - Patrick R Lawler
- Clinical Trials and Translation Unit, Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada; McGill University Health Centre, McGill University, Montréal, Québec, Canada.
| |
Collapse
|
14
|
Navarese EP, Lansky AJ, Farkouh ME, Grzelakowska K, Bonaca MP, Gorog DA, Raggi P, Kelm M, Yeo B, Umińska J, Curzen N, Kubica J, Wijns W, Kereiakes DJ. Effects of Elective Coronary Revascularization vs Medical Therapy Alone on Noncardiac Mortality: A Meta-Analysis. JACC Cardiovasc Interv 2023; 16:1144-1156. [PMID: 37225285 DOI: 10.1016/j.jcin.2023.02.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2022] [Revised: 02/16/2023] [Accepted: 02/21/2023] [Indexed: 05/26/2023]
Abstract
BACKGROUND Uncertainty exists whether coronary revascularization plus medical therapy (MT) is associated with an increase in noncardiac mortality in chronic coronary syndrome (CCS) when compared with MT alone, particularly following recent data from the ISCHEMIA-EXTEND (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial. OBJECTIVES This study conducted a large-scale meta-analysis of trials comparing elective coronary revascularization plus MT vs MT alone in patients with CCS to determine whether revascularization has a differential impact on noncardiac mortality at the longest follow-up. METHODS We searched for randomized trials comparing revascularization plus MT vs MT alone in patients with CCS. Treatment effects were measured by rate ratios (RRs) with 95% CIs, using random-effects models. Noncardiac mortality was the prespecified endpoint. The study is registered with PROSPERO (CRD42022380664). RESULTS Eighteen trials were included involving 16,908 patients randomized to either revascularization plus MT (n = 8,665) or to MT alone (n = 8,243). No significant differences were detected in noncardiac mortality between the assigned treatment groups (RR: 1.09; 95% CI: 0.94-1.26; P = 0.26), with absent heterogeneity (I2 = 0%). Results were consistent without the ISCHEMIA trial (RR: 1.00; 95% CI: 0.84-1.18; P = 0.97). By meta-regression, follow-up duration did not affect noncardiac death rates with revascularization plus MT vs MT alone (P = 0.52). Trial sequential analysis confirmed the reliability of meta-analysis, with the cumulative Z-curve of trial evidence within the nonsignificance area and reaching futility boundaries. Bayesian meta-analysis findings were consistent with the standard approach (RR: 1.08; 95% credible interval: 0.90-1.31). CONCLUSIONS In patients with CCS, noncardiac mortality in late follow-up was similar for revascularization plus MT compared with MT alone.
Collapse
Affiliation(s)
- Eliano P Navarese
- Interventional Cardiology and Cardiovascular Medicine Research, Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland; Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada; SIRIO MEDICINE Research Network, Bydgoszcz, Poland.
| | | | - Michael E Farkouh
- Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada; Cedars Sinai Health System, Los Angeles, CA
| | - Klaudyna Grzelakowska
- Interventional Cardiology and Cardiovascular Medicine Research, Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland; SIRIO MEDICINE Research Network, Bydgoszcz, Poland
| | - Marc P Bonaca
- CPC Clinical Research, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Diana A Gorog
- Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom; Cardiology Department, East and North Hertfordshire NHS Trust, Stevenage, United Kingdom
| | - Paolo Raggi
- Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Malte Kelm
- Heinrich Heine University Medical Center Düsseldorf, Düsseldorf, Germany; Division of Cardiology, Pulmonology, and Vascular Medicine, Cardiovascular Research Institute Düsseldorf, Düsseldorf, Germany
| | - Brandon Yeo
- Interventional Cardiology and Cardiovascular Medicine Research, Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland; SIRIO MEDICINE Research Network, Bydgoszcz, Poland
| | - Julia Umińska
- Interventional Cardiology and Cardiovascular Medicine Research, Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland; SIRIO MEDICINE Research Network, Bydgoszcz, Poland
| | - Nick Curzen
- University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom; University of Southampton, Southampton, United Kingdom
| | - Jacek Kubica
- Interventional Cardiology and Cardiovascular Medicine Research, Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland; SIRIO MEDICINE Research Network, Bydgoszcz, Poland
| | - William Wijns
- Lambe Institute for Translational Medicine and CÚRAM, National University of Ireland Galway and Saolta University Healthcare Group, Galway, Ireland
| | - Dean J Kereiakes
- Christ Hospital and Lindner Research Center, Cincinnati, Ohio, USA
| |
Collapse
|
15
|
Nguyen A, Khafagy R, Gao Y, Meerasa A, Roshandel D, Anvari M, Lin B, Cherney DZI, Farkouh ME, Shah BR, Paterson AD, Dash S. Erratum. Association Between Obesity and Chronic Kidney Disease: Multivariable Mendelian Randomization Analysis and Observational Data From a Bariatric Surgery Cohort. Diabetes 2023;72:496-510. Diabetes 2023:148944. [PMID: 37200064 PMCID: PMC10382645 DOI: 10.2337/db23-er08a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
In Table 2 of the article cited above, the univariable MR analyses for microalbuminuria were erroneously cited as inverse variance weighted analyses. The row headings in Table 2 have been revised to show the correct analyses performed: MR-Egger, weighted median and mode, and simple mode analyses. In Fig. 3, the confidence intervals were erroneously plotted as error bars. Fig. 3 has been updated with the correct confidence intervals from the text. The revised online version of the article can be accessed at https://doi.org/10.2337/db22-0696.
Collapse
|
16
|
Kovacs AH, Lebovic G, Raptis S, Blais S, Caldarone CA, Dahdah N, Dallaire F, Drolet C, Grewal J, Hancock Friesen CL, Hickey E, Karur GR, Khairy P, Leonardi B, Keir M, McCrindle BW, Nadeem SN, Ng MY, Shah AH, Tham EB, Therrien J, Warren AE, Vonder Muhll IF, Van de Bruaene A, Yamamura K, Farkouh ME, Wald RM. Patient-Reported Outcomes After Tetralogy of Fallot Repair. J Am Coll Cardiol 2023; 81:1937-1950. [PMID: 37164527 DOI: 10.1016/j.jacc.2023.03.385] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Revised: 02/01/2023] [Accepted: 03/02/2023] [Indexed: 05/12/2023]
Abstract
BACKGROUND Comprehensive assessment of tetralogy of Fallot (TOF) outcomes extends beyond morbidity and mortality to incorporate patient-reported outcomes (PROs), including quality of life (QOL) and health status (HS). OBJECTIVES This study explored PROs in adolescents and adults with TOF and delineated variables associated with PROs. METHODS This was a cross-sectional observational study within a larger prospective registry of adolescents and adults with repaired TOF and moderate or greater pulmonary regurgitation from North America, Europe, and Asia. Participants completed PROs, including a QOL linear analogue scale (QOL-LAS) and an HS visual analogue scale (HS-VAS). Scores were classified according to age cohorts: <18, 18 to 25, 26 to 40, and >40 years. RESULTS The study included 607 patients (46.3% female; median age 28.5 years). Median QOL-LAS scores (0-100) were similar across age cohorts (85, 80, 80, 80; P = 0.056). Median HS-VAS scores (0-100) were lowest for the oldest cohort (77) compared with the 3 younger cohorts (85, 80, 80) (P = 0.004). With advancing age, there were increased reports of poor mobility (P < 0.001) and pain or discomfort (P = 0.004); problems in these dimensions were reported by 19.1% and 37.2% of patients aged >40 years, respectively. Of factors associated with superior PROs on multivariable regression modeling (ie, being White, being nonsyndromic, having employment, and having better left ventricular function; P < 0.05), asymptomatic status (functional class I) was the variable associated with the greatest number of QOL and HS measures (P < 0.001). CONCLUSIONS Strategies to improve TOF outcomes should consider PROs alongside conventional clinical variables. Factors associated with poorer PROs represent opportunities to intervene to improve the lives of patients with TOF.
Collapse
Affiliation(s)
- Adrienne H Kovacs
- Equilibria Psychological Health, Toronto, Ontario, Canada; Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada
| | - Gerald Lebovic
- Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, Ontario, Canada
| | - Stavroula Raptis
- Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, Ontario, Canada
| | - Samuel Blais
- Division of Pediatrics, University of Sherbrooke, Sherbrokke, Quebec, Canada; Research Centre of the Sherbrooke University Hospital, Sherbrooke, Quebec, Canada
| | | | - Nagib Dahdah
- Division of Pediatric Cardiology, Sainte-Justine University Hospital Center, Montreal, Quebec, Canada
| | - Frédéric Dallaire
- Division of Pediatrics, University of Sherbrooke, Sherbrokke, Quebec, Canada; Research Centre of the Sherbrooke University Hospital, Sherbrooke, Quebec, Canada
| | - Christian Drolet
- Division of Pediatric and Congenital Cardiology, Department of Pediatrics, Laval University Hospital, Quebec City, Quebec, Canada
| | - Jasmine Grewal
- Yasmin and Amir Virani Provincial Adult Congenital Heart Program, Vancouver, British Columbia, Canada
| | | | - Edward Hickey
- Division of Cardiovascular Surgery, Texas Children's Hospital, Houston, Texas, USA
| | - Gauri Rani Karur
- Joint Department of Medical Imaging, University Health Network, Toronto, Ontario, Canada
| | - Paul Khairy
- Adult Congenital Center, Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada
| | - Benedetta Leonardi
- Department of Pediatric Cardiology, Cardiac Surgery and Heart Lung Transplantation, Bambino Gesù Hospital and Research Institute, Scientific Institute for Research, Hospitalization, and Health Care, Rome, Italy
| | - Michelle Keir
- Southern Alberta Adult Congenital Heart Disease Clinic, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada
| | - Brian W McCrindle
- Labatt Family Heart Centre, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
| | - Syed Najaf Nadeem
- Division of Cardiology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
| | - Ming-Yen Ng
- Department of Diagnostic Radiology, School of Clinical Medicine, The University of Hong Kong, Hong Kong; Department of Medical Imaging, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
| | - Ashish H Shah
- Division of Cardiology, University of Manitoba, Winnipeg, Manitoba, Canada
| | - Edythe B Tham
- Pediatric Cardiology, Stollery Children's Hospital, Edmonton, Alberta, Canada
| | - Judith Therrien
- MAUDE Unit (McGill University Health Network/Beth Raby Adult Congenital Heart Disease Clinic, Jewish General Hospital), Montreal, Quebec, Canada
| | - Andrew E Warren
- Division of Pediatric Cardiology, Dalhousie University, Halifax, Nova Scotia, Canada
| | | | | | | | - Michael E Farkouh
- Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada
| | - Rachel M Wald
- Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada; Joint Department of Medical Imaging, University Health Network, Toronto, Ontario, Canada; Labatt Family Heart Centre, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; Division of Cardiology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
| |
Collapse
|
17
|
Stone GW, Farkouh ME, Lala A, Tinuoye E, Dressler O, Moreno PR, Palacios IF, Goodman SG, Esper RB, Abizaid A, Varade D, Betancur JF, Ricalde A, Payro G, Castellano JM, Hung IFN, Nadkarni GN, Giustino G, Godoy LC, Feinman J, Camaj A, Bienstock SW, Furtado RHM, Granada C, Bustamante J, Peyra C, Contreras J, Owen R, Bhatt DL, Pocock SJ, Fuster V. Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19. J Am Coll Cardiol 2023; 81:1747-1762. [PMID: 36889611 PMCID: PMC9987252 DOI: 10.1016/j.jacc.2023.02.041] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Accepted: 02/27/2023] [Indexed: 03/08/2023]
Abstract
BACKGROUND Prior studies of therapeutic-dose anticoagulation in patients with COVID-19 have reported conflicting results. OBJECTIVES We sought to determine the safety and effectiveness of therapeutic-dose anticoagulation in noncritically ill patients with COVID-19. METHODS Patients hospitalized with COVID-19 not requiring intensive care unit treatment were randomized to prophylactic-dose enoxaparin, therapeutic-dose enoxaparin, or therapeutic-dose apixaban. The primary outcome was the 30-day composite of all-cause mortality, requirement for intensive care unit-level of care, systemic thromboembolism, or ischemic stroke assessed in the combined therapeutic-dose groups compared with the prophylactic-dose group. RESULTS Between August 26, 2020, and September 19, 2022, 3,398 noncritically ill patients hospitalized with COVID-19 were randomized to prophylactic-dose enoxaparin (n = 1,141), therapeutic-dose enoxaparin (n = 1,136), or therapeutic-dose apixaban (n = 1,121) at 76 centers in 10 countries. The 30-day primary outcome occurred in 13.2% of patients in the prophylactic-dose group and 11.3% of patients in the combined therapeutic-dose groups (HR: 0.85; 95% CI: 0.69-1.04; P = 0.11). All-cause mortality occurred in 7.0% of patients treated with prophylactic-dose enoxaparin and 4.9% of patients treated with therapeutic-dose anticoagulation (HR: 0.70; 95% CI: 0.52-0.93; P = 0.01), and intubation was required in 8.4% vs 6.4% of patients, respectively (HR: 0.75; 95% CI: 0.58-0.98; P = 0.03). Results were similar in the 2 therapeutic-dose groups, and major bleeding in all 3 groups was infrequent. CONCLUSIONS Among noncritically ill patients hospitalized with COVID-19, the 30-day primary composite outcome was not significantly reduced with therapeutic-dose anticoagulation compared with prophylactic-dose anticoagulation. However, fewer patients who were treated with therapeutic-dose anticoagulation required intubation and fewer died (FREEDOM COVID [FREEDOM COVID Anticoagulation Strategy]; NCT04512079).
Collapse
Affiliation(s)
- Gregg W Stone
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Michael E Farkouh
- Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada
| | - Anuradha Lala
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Elizabeth Tinuoye
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | | | - Pedro R Moreno
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | | | - Shaun G Goodman
- St Michael's Hospital, Unity Heath, University of Toronto, Toronto, Ontario, Canada; Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada
| | | | - Alexandre Abizaid
- Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil
| | | | | | | | - Gerardo Payro
- Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran, Mexico City, Mexico
| | - José María Castellano
- Centro Integral de Enfermedades Cardiovasculares (CIEC), Hospital Universitario Monterpincipe, Grupo HM Hospitales, Madrid, Spain
| | | | - Girish N Nadkarni
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; The Charles Bronfman Institute of Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Division of Data Driven and Digital Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Gennaro Giustino
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Lucas C Godoy
- Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada
| | - Jason Feinman
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Anton Camaj
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Solomon W Bienstock
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | | | - Carlos Granada
- CogenTech Medical and Digital Innovation, Mahwah, New Jersey, USA
| | - Jessica Bustamante
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Carlos Peyra
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Johanna Contreras
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Ruth Owen
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Deepak L Bhatt
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Stuart J Pocock
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Valentin Fuster
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
| |
Collapse
|
18
|
Berger JS, Neal MD, Kornblith LZ, Gong MN, Reynolds HR, Cushman M, Althouse AD, Lawler PR, McVerry BJ, Kim KS, Baumann Kreuziger L, Solomon SD, Kosiborod MN, Berry SM, Bochicchio GV, Contoli M, Farkouh ME, Froess JD, Gandotra S, Greenstein Y, Hade EM, Hanna N, Hudock K, Hyzy RC, Ibáñez Estéllez F, Iovine N, Khanna AK, Khatri P, Kirwan BA, Kutcher ME, Leifer E, Lim G, Lopes RD, Lopez-Sendon JL, Luther JF, Nigro Maia L, Quigley JG, Wahid L, Wilson JG, Zarychanski R, Kindzelski A, Geraci MW, Hochman JS. Effect of P2Y12 Inhibitors on Organ Support-Free Survival in Critically Ill Patients Hospitalized for COVID-19: A Randomized Clinical Trial. JAMA Netw Open 2023; 6:e2314428. [PMID: 37227729 DOI: 10.1001/jamanetworkopen.2023.14428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
Importance Platelet activation is a potential therapeutic target in patients with COVID-19. Objective To evaluate the effect of P2Y12 inhibition among critically ill patients hospitalized for COVID-19. Design, Setting, and Participants This international, open-label, adaptive platform, 1:1 randomized clinical trial included critically ill (requiring intensive care-level support) patients hospitalized with COVID-19. Patients were enrolled between February 26, 2021, through June 22, 2022. Enrollment was discontinued on June 22, 2022, by the trial leadership in coordination with the study sponsor given a marked slowing of the enrollment rate of critically ill patients. Intervention Participants were randomly assigned to receive a P2Y12 inhibitor or no P2Y12 inhibitor (usual care) for 14 days or until hospital discharge, whichever was sooner. Ticagrelor was the preferred P2Y12 inhibitor. Main Outcomes and Measures The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death and, for participants who survived to hospital discharge, the number of days free of cardiovascular or respiratory organ support up to day 21 of the index hospitalization. The primary safety outcome was major bleeding, as defined by the International Society on Thrombosis and Hemostasis. Results At the time of trial termination, 949 participants (median [IQR] age, 56 [46-65] years; 603 male [63.5%]) had been randomly assigned, 479 to the P2Y12 inhibitor group and 470 to usual care. In the P2Y12 inhibitor group, ticagrelor was used in 372 participants (78.8%) and clopidogrel in 100 participants (21.2%). The estimated adjusted odds ratio (AOR) for the effect of P2Y12 inhibitor on organ support-free days was 1.07 (95% credible interval, 0.85-1.33). The posterior probability of superiority (defined as an OR > 1.0) was 72.9%. Overall, 354 participants (74.5%) in the P2Y12 inhibitor group and 339 participants (72.4%) in the usual care group survived to hospital discharge (median AOR, 1.15; 95% credible interval, 0.84-1.55; posterior probability of superiority, 80.8%). Major bleeding occurred in 13 participants (2.7%) in the P2Y12 inhibitor group and 13 (2.8%) in the usual care group. The estimated mortality rate at 90 days for the P2Y12 inhibitor group was 25.5% and for the usual care group was 27.0% (adjusted hazard ratio, 0.96; 95% CI, 0.76-1.23; P = .77). Conclusions and Relevance In this randomized clinical trial of critically ill participants hospitalized for COVID-19, treatment with a P2Y12 inhibitor did not improve the number of days alive and free of cardiovascular or respiratory organ support. The use of the P2Y12 inhibitor did not increase major bleeding compared with usual care. These data do not support routine use of a P2Y12 inhibitor in critically ill patients hospitalized for COVID-19. Trial Registration ClinicalTrials.gov Identifier: NCT04505774.
Collapse
Affiliation(s)
- Jeffrey S Berger
- Center for the Prevention of Cardiovascular Disease, NYU Grossman School of Medicine, New York, New York
| | - Matthew D Neal
- Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Lucy Z Kornblith
- Department of Surgery, University of California, San Francisco, San Francisco
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco
| | | | - Harmony R Reynolds
- Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, New York
| | - Mary Cushman
- University of Vermont College of Medicine, Burlington
| | - Andrew D Althouse
- Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
- Now with Medtronic, Minneapolis, Minnesota
| | | | - Bryan J McVerry
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Keri S Kim
- College of Pharmacy, University of Illinois at Chicago, Chicago
| | | | - Scott D Solomon
- Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Mikhail N Kosiborod
- Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City
| | | | | | - Marco Contoli
- Department of Translational Medicine, Università di Ferrara, Ferrara, Italy
| | | | - Joshua D Froess
- Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Sheetal Gandotra
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama, Birmingham
| | | | - Erinn M Hade
- Division of Biostatistics, Department of Population Health, NYU Grossman School of Medicine, New York, New York
| | - Nicholas Hanna
- Ascension St John Clinical Research Institute, Tulsa, Oklahoma
| | - Kristin Hudock
- University of Cincinnati Medical Center, Cincinnati, Ohio
| | - Robert C Hyzy
- Division of Pulmonary and Critical Care, Department of Medicine, University of Michigan, Ann Arbor
| | | | - Nicole Iovine
- Division of Infectious Diseases and Global Medicine, Department of Medicine, University of Florida, Gainesville
| | - Ashish K Khanna
- Perioperative Outcomes and Informatics Collaborative, Wake Forest University School of Medicine, Winston-Salem, North Carolina
- Outcomes Research Consortium, Cleveland, Ohio
| | - Pooja Khatri
- University of Cincinnati Medical Center, Cincinnati, Ohio
| | | | | | - Eric Leifer
- National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | - George Lim
- Ronald Reagan UCLA Medical Center, Los Angeles, California
| | - Renato D Lopes
- Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham
| | | | - James F Luther
- Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Lilia Nigro Maia
- Fundação Faculdade Regional De Medicina De São José Do Rio Preto, São José do Rio Preto, Brazil
| | - John G Quigley
- Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago
| | - Lana Wahid
- Division of Internal Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina
| | | | - Ryan Zarychanski
- Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
| | - Andrei Kindzelski
- National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | - Mark W Geraci
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Judith S Hochman
- Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, New York
| |
Collapse
|
19
|
Behrouzi B, Sivaswamy A, Chu A, Ferreira-Legere LE, Abdel-Qadir H, Atzema CL, Jackevicius C, Kapral MK, Wijeysundera HC, Farkouh ME, Ross HJ, Ha ACT, Tadrous M, Paterson M, Gershon AS, Džavík V, Fang J, Kaul P, van Diepen S, Goodman SG, Ezekowitz JA, Bainey KR, Ko DT, Austin PC, McAlister FA, Lee DS, Udell JA. Sex-Based Differences in Severe Outcomes, Including Cardiovascular Hospitalization, in Adults With COVID-19 in Ontario, Canada. JACC Adv 2023; 2:100307. [PMID: 37250382 PMCID: PMC10171238 DOI: 10.1016/j.jacadv.2023.100307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 12/30/2022] [Accepted: 02/08/2023] [Indexed: 05/31/2023]
Abstract
Background While men have experienced higher risks of SARS-CoV-2 infection compared to women, an analysis of sex differences by age in severe outcomes during the acute phase of infection is lacking. Objectives The purpose of this study was to assess heterogeneity in severe outcome risks by age and sex by conducting a retrospective cohort study of community-dwelling adults in Ontario who tested positive for SARS-CoV-2 infection during the first 3 waves. Methods Adjusted odds ratios were estimated using multilevel multivariable logistic regression models including an interaction term for age and sex. The primary outcome was a composite of severe outcomes (hospitalization for a cardiovascular (CV) event, intensive care unit admission, mechanical ventilation, or death) within 30 days. Results Among 30,736, 199,132, and 186,131 adults who tested positive during the first 3 waves, 1,908 (6.2%), 5,437 (2.7%), and 5,653 (3.0%) experienced a severe outcome within 30 days. For all outcomes, the sex-specific risk depended on age (all P for interaction <0.05). Men with SARS-CoV-2 infection experienced a higher risk of outcomes than infected women of the same age, except for the risk of all-cause hospitalization being higher for young women than men (ages 18-45 years) during waves 2 and 3. The sex disparity in CV hospitalization across all ages either persisted or increased with each subsequent wave. Conclusions To mitigate risks in subsequent waves, it is helpful to further understand the factors that contribute to the generally higher risks faced by men across all ages, and the persistent or increasing sex disparity in the risk of CV hospitalization.
Collapse
Affiliation(s)
- Bahar Behrouzi
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
- Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
- Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, Canada
| | | | | | | | - Husam Abdel-Qadir
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
- Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
- Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, Canada
- Department of Medicine, University of Toronto, Toronto, Canada
| | - Clare L Atzema
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
- Department of Medicine, University of Toronto, Toronto, Canada
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada
| | - Cynthia Jackevicius
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
- College of Pharmacy, Western University of Health Sciences, Pomona, California, USA
| | - Moira K Kapral
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
- Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
- Department of Medicine, University of Toronto, Toronto, Canada
| | - Harindra C Wijeysundera
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
- Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada
| | - Michael E Farkouh
- Peter Munk Cardiac Centre, University Health Network, Toronto, Canada
- Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Canada
| | - Heather J Ross
- Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
- Peter Munk Cardiac Centre, University Health Network, Toronto, Canada
| | - Andrew C T Ha
- Department of Medicine, University of Toronto, Toronto, Canada
- Peter Munk Cardiac Centre, University Health Network, Toronto, Canada
| | - Mina Tadrous
- ICES, Toronto, Canada
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada
- Women's College Research Institute, Toronto, Canada
| | - Michael Paterson
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
| | - Andrea S Gershon
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
- Department of Medicine, University of Toronto, Toronto, Canada
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada
| | - Vladimír Džavík
- Peter Munk Cardiac Centre, University Health Network, Toronto, Canada
| | | | - Padma Kaul
- Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada
- Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada
- Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Canada
| | - Sean van Diepen
- Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada
- Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada
- Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Canada
| | - Shaun G Goodman
- Department of Medicine, University of Toronto, Toronto, Canada
- Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada
- Division of Cardiology, St. Michael's Hospital, Toronto, Canada
| | - Justin A Ezekowitz
- Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada
- Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada
- Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Canada
| | - Kevin R Bainey
- Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada
- Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada
- Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Canada
| | - Dennis T Ko
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
- Department of Medicine, University of Toronto, Toronto, Canada
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada
| | - Peter C Austin
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
| | - Finlay A McAlister
- Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada
- Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada
- Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Canada
| | - Douglas S Lee
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
- Department of Medicine, University of Toronto, Toronto, Canada
- Peter Munk Cardiac Centre, University Health Network, Toronto, Canada
| | - Jacob A Udell
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
- ICES, Toronto, Canada
- Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, Canada
- Department of Medicine, University of Toronto, Toronto, Canada
- Peter Munk Cardiac Centre, University Health Network, Toronto, Canada
| |
Collapse
|
20
|
Sakhuja S, Bittner VA, Brown TM, Farkouh ME, Levitan EB, Safford MM, Woodward M, Chen L, Sun R, Dhalwani N, Jones J, Kalich B, Exter J, Muntner P, Rosenson RS, Colantonio LD. Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction. Cardiovasc Drugs Ther 2023:10.1007/s10557-023-07452-1. [PMID: 37052867 DOI: 10.1007/s10557-023-07452-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/30/2023] [Indexed: 04/14/2023]
Abstract
PURPOSE Many adults with atherosclerotic cardiovascular disease (ASCVD) who are recommended to take a statin, ezetimibe and/or a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) by the 2018 American Heart Association/American College of Cardiology cholesterol guideline do not receive these medications. We estimated the percentage of recurrent ASCVD events potentially prevented with guideline-recommended cholesterol-lowering therapy following a myocardial infarction (MI) hospitalization. METHODS We conducted simulations using data from US adults with government health insurance through Medicare or commercial health insurance in the MarketScan database. We used data from patients with an MI hospitalization in 2018-2019 to estimate the percentage receiving guideline-recommended therapy. We used data from patients with an MI hospitalization in 2013-2016 to estimate the 3-year cumulative incidence of recurrent ASCVD events (i.e., MI, coronary revascularization or ischemic stroke). The low-density lipoprotein cholesterol (LDL-C) reduction with guideline-recommended therapy was derived from trials of statins, ezetimibe and PCSK9i, and the associated ASCVD risk reduction was estimated from a meta-analysis by the Cholesterol-Lowering Treatment Trialists Collaboration. RESULTS Among 279,395 patients with an MI hospitalization in 2018-2019 (mean age 75 years, mean LDL-C 92 mg/dL), 27.3% were receiving guideline-recommended cholesterol-lowering therapy. With current cholesterol-lowering therapy use, 25.3% (95%CI: 25.2%-25.4%) of patients had an ASCVD event over 3 years. If all patients were to receive guideline-recommended therapy, 19.8% (95%CI: 19.5%-19.9%) were estimated to have an ASCVD event over 3 years, representing a 21.6% (95%CI: 20.5%-23.6%) relative risk reduction. CONCLUSION Implementation of guideline-recommended cholesterol-lowering therapy could prevent a substantial percentage of recurrent ASCVD events.
Collapse
Affiliation(s)
- Swati Sakhuja
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
| | - Vera A Bittner
- Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Todd M Brown
- Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Michael E Farkouh
- Peter Munk Cardiac Centre, University of Toronto and Heart and Stroke Richard Lewar Centre of Excellence, Toronto, ON, Canada
| | - Emily B Levitan
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Monika M Safford
- Department of Medicine, Weill Cornell Medicine, New York, NY, USA
| | - Mark Woodward
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
- The George Institute for Global Health, School of Public Health, Imperial College, London, UK
| | - Ligong Chen
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Ruoyan Sun
- Department of Healthcare Policy and Organization and Policy, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Nafeesa Dhalwani
- Center for Observational Research, Amgen Inc., Thousand Oaks, CA, USA
| | - Jenna Jones
- Center for Observational Research, Amgen Inc., Thousand Oaks, CA, USA
| | | | | | - Paul Muntner
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Robert S Rosenson
- Icahn School of Medicine at Mount Sinai, Mount Sinai Heart, New York, NY, USA
| | - Lisandro D Colantonio
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA
| |
Collapse
|
21
|
Ingraham BS, Farkouh ME, Lennon RJ, So D, Goodman SG, Geller N, Bae JH, Jeong MH, Baudhuin LM, Mathew V, Bell MR, Lerman A, Fu YP, Hasan A, Iturriaga E, Tanguay JF, Welsh RC, Rosenberg Y, Bailey K, Rihal C, Pereira NL. Genetic-Guided Oral P2Y 12 Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention. JACC Cardiovasc Interv 2023; 16:816-825. [PMID: 37045502 PMCID: PMC10498663 DOI: 10.1016/j.jcin.2023.01.356] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 01/10/2023] [Accepted: 01/17/2023] [Indexed: 04/14/2023]
Abstract
BACKGROUND Genetic-guided P2Y12 inhibitor selection has been proposed to reduce ischemic events by identifying CYP2C19 loss-of-function (LOF) carriers at increased risk with clopidogrel treatment after percutaneous coronary intervention (PCI). A prespecified analysis of TAILOR-PCI (Tailored Antiplatelet Therapy Following PCI) evaluated the effect of genetic-guided P2Y12 inhibitor therapy on cumulative ischemic and bleeding events. OBJECTIVES Here, the authors detail a prespecified analysis of cumulative endpoints. The primary endpoint was cumulative incidence rate of ischemic events at 12 months. Cumulative incidence of major and minor bleeding was a secondary endpoint. Cox proportional hazards models as adapted by Wei, Lin, and Weissfeld were used to estimate the effect of this strategy on all observed events. METHODS The TAILOR-PCI trial was a prospective trial including 5,302 post-PCI patients with acute and stable coronary artery disease (CAD) who were randomized to genetic-guided P2Y12 inhibitor or conventional clopidogrel therapy. In the genetic-guided group, LOF carriers were prescribed ticagrelor, whereas noncarriers received clopidogrel. TAILOR-PCI's primary analysis was time to first event in LOF carriers. RESULTS Among 5,276 patients (median age 62 years; 25% women; 82% acute CAD; 18% stable CAD), 1,849 were LOF carriers (903 genetic-guided; 946 conventional therapy). The cumulative primary endpoint was significantly reduced in the genetic-guided group compared with the conventional therapy (HR: 0.61; 95% CI: 0.41-0.89; P = 0.011) with no significant difference in cumulative incidence of major or minor bleeding (HR: 1.36; 95% CI: 0.67-2.76; P = 0.39). CONCLUSIONS Among CYP2C19 LOF carriers undergoing PCI, a genetic-guided strategy resulted in a statistically significant reduction in cumulative ischemic events without a significant difference in bleeding. (Tailored Antiplatelet Therapy Following PCI [TAILOR-PCI]; NCT01742117).
Collapse
Affiliation(s)
- Brenden S Ingraham
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Michael E Farkouh
- Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada
| | - Ryan J Lennon
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA
| | - Derek So
- University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Shaun G Goodman
- St. Michael's Hospital, University of Toronto, Toronto, Canada; Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada
| | - Nancy Geller
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Jang-Ho Bae
- Department of Internal Medicine, Division of Cardiology, Konyang University, Seo-gu, Taejon, South Korea
| | - Myung Ho Jeong
- Heart Research Center, Chonnam National University, Gwangju, South Korea
| | - Linnea M Baudhuin
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
| | - Verghese Mathew
- Worldwide Network of Innovation in Clinical Education and Research (WNICER) Institute, New York, New York, USA
| | - Malcolm R Bell
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Amir Lerman
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Yi-Ping Fu
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Ahmed Hasan
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Erin Iturriaga
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | | | - Robert C Welsh
- Department of Medicine, Mazankowski Alberta Heart Institute and University of Alberta, Edmonton, Alberta, Canada
| | - Yves Rosenberg
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Kent Bailey
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA
| | - Charanjit Rihal
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Naveen L Pereira
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
| |
Collapse
|
22
|
Nguyen A, Khafagy R, Gao Y, Meerasa A, Roshandel D, Anvari M, Lin B, Cherney DZI, Farkouh ME, Shah BR, Paterson AD, Dash S. Association Between Obesity and Chronic Kidney Disease: Multivariable Mendelian Randomization Analysis and Observational Data From a Bariatric Surgery Cohort. Diabetes 2023; 72:496-510. [PMID: 36657976 DOI: 10.2337/db22-0696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Accepted: 01/10/2023] [Indexed: 01/21/2023]
Abstract
Obesity is postulated to independently increase chronic kidney disease (CKD), even after adjusting for type 2 diabetes (T2D) and hypertension. Dysglycemia below T2D thresholds, frequently seen with obesity, also increases CKD risk. Whether obesity increases CKD independent of dysglycemia and hypertension is unknown and likely influences the optimal weight loss (WL) needed to reduce CKD. T2D remission rates plateau with 20-25% WL after bariatric surgery (BS), but further WL increases normoglycemia and normotension. We undertook bidirectional inverse variance weighted Mendelian randomization (IVWMR) to investigate potential independent causal associations between increased BMI and estimated glomerular filtration rate (eGFR) in CKD (CKDeGFR) (<60 mL/min/1.73 m2) and microalbuminuria (MA). In 5,337 BS patients, we assessed whether WL influences >50% decline in eGFR (primary outcome) or CKD hospitalization (secondary outcome), using <20% WL as a comparator. IVWMR results suggest that increased BMI increases CKDeGFR (b = 0.13, P = 1.64 × 10-4; odds ratio [OR] 1.14 [95% CI 1.07, 1.23]) and MA (b = 0.25; P = 2.14 × 10-4; OR 1.29 [1.13, 1.48]). After adjusting for hypertension and fasting glucose, increased BMI did not significantly increase CKDeGFR (b = -0.02; P = 0.72; OR 0.98 [0.87, 1.1]) or MA (b = 0.19; P = 0.08; OR 1.21 [0.98, 1.51]). Post-BS WL significantly reduced the primary outcome with 30 to <40% WL (hazard ratio [HR] 0.53 [95% CI 0.32, 0.87]) but not 20 to <30% WL (HR 0.72 [0.44, 1.2]) and ≥40% WL (HR 0.73 [0.41, 1.30]). For CKD hospitalization, progressive reduction was seen with increased WL, which was significant for 30 to <40% WL (HR 0.37 [0.17, 0.82]) and ≥40% WL (HR 0.24 [0.07, 0.89]) but not 20 to <30% WL (HR 0.60 [0.29, 1.23]). The data suggest that obesity is likely not an independent cause of CKD. WL thresholds previously associated with normotension and normoglycemia, likely causal mediators, may reduce CKD after BS.
Collapse
Affiliation(s)
- Anthony Nguyen
- Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada
| | - Rana Khafagy
- Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada
- Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Divisions of Epidemiology and Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - Yiding Gao
- Division of Endocrinology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Ameena Meerasa
- Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada
| | - Delnaz Roshandel
- Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Mehran Anvari
- Department of Surgery, St. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada
| | - Boxi Lin
- Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - David Z I Cherney
- Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada
| | - Michael E Farkouh
- Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada
- Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
| | - Baiju R Shah
- Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada
- Division of Endocrinology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- ICES, Toronto, Ontario, Canada
| | - Andrew D Paterson
- Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Divisions of Epidemiology and Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - Satya Dash
- Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
23
|
Lytvyn Y, Felfeli T, Dubrofsky L, Dharia A, Lee JF, Sutakovic O, Nash C, Oliver T, Ong SW, Udell JA, Farkouh ME, Lawler PR, Weisman A, Lovshin JA, Cherney DZ, Brent MH. Diabetic retinopathy screening integrated in a multidisciplinary diabetes care clinic: a pilot project of cardiac and renal endocrine clinic. Canadian Journal of Ophthalmology 2023:S0008-4182(23)00067-4. [PMID: 37023796 DOI: 10.1016/j.jcjo.2023.02.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Revised: 02/07/2023] [Accepted: 02/26/2023] [Indexed: 04/05/2023]
Abstract
OBJECTIVE To characterize patients referred for diabetic retinopathy (DR) screening in a unique multidisciplinary diabetes care clinic at a tertiary care centre. METHODS A retrospective study was conducted involving patients who were referred to the Cardiac and Renal Endocrine Clinic at a tertiary care centre (University Health Network) for DR screening between April 2019-March 2020 and November 2020-August 2021. Patients' demographics; micro- and macrovascular disease measurements; and visual acuity, intraocular pressure, fundus imaging, and optical coherence tomography results were collected and analyzed. RESULTS Of the 64 patients who attended the clinic, 21 patients (33%) with type 2 diabetes had on-site DR screening. The remaining 43 patients had DR screening within 6 months of the appointment or were under ophthalmology care with annual screening visits elsewhere. Of the 21 patients who underwent retinopathy screening, 7 patients (33%) had DR: 4 had mild nonproliferative DR, 2 had moderate nonproliferative DR, 1 had proliferative DR, and 1 had macular edema. Patients with DR had a significantly longer diabetes duration than patients without DR (24.5 ± 10.2 years vs 12.5 ± 5.8 years; p = 0.0247). No significant differences were observed in glycemic control, blood pressure, lipid profiles, kidney function, visual acuity, or intraocular pressure. CONCLUSIONS Our analysis suggests a potential benefit of integrated DR screening in patients with long-standing diabetes as part of a multidisciplinary diabetes care clinic to diagnose and manage DR. Future work is needed to further develop such clinics and investigate their long-term effect on patient outcomes.
Collapse
|
24
|
Domanski MJ, Wu CO, Tian X, Hasan AA, Ma X, Huang Y, Miao R, Reis JP, Bae S, Husain A, Jacobs DR, Allen NB, Lee MLT, Hong CC, Farkouh ME, Lloyd-Jones DM, Fuster V. Association of Incident Cardiovascular Disease With Time Course and Cumulative Exposure to Multiple Risk Factors. J Am Coll Cardiol 2023; 81:1151-1161. [PMID: 36948731 DOI: 10.1016/j.jacc.2023.01.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Revised: 01/06/2023] [Accepted: 01/17/2023] [Indexed: 03/24/2023]
Abstract
BACKGROUND The quantitative relationship of incident cardiovascular disease (CVD) to lifetime cumulative risk factor exposure is not well understood. OBJECTIVES Using CARDIA (Coronary Artery Risk Development in Young Adults) study data, we examined the quantitative associations of cumulative exposure over time to multiple, simultaneously operating risk factors with CVD incidence and the incidence of its components. METHODS Regression models were developed quantifying the influence of the time course and severity of multiple CVD risk factors, operating simultaneously, on risk of incident CVD. The outcomes were incident CVD and the incidence of its components: coronary heart disease, stroke, and congestive heart failure. RESULTS Our study included 4,958 asymptomatic adults enrolled in CARDIA from 1985 to 1986 (ages 18 to 30 years) who were followed for 30 years. Risk of incident CVD depends on the time course and severity of a series of independent risk factors, the impact of which is mediated by their effects on individual CVD components after age 40 years. Cumulative exposure (AUC vs time) to low-density lipoprotein cholesterol and triglycerides was independently associated with risk of incident CVD. Of the blood pressure variables, areas under the mean arterial pressure vs time curve and the pulse pressure vs time curve were strongly and independently associated with incident CVD risk. CONCLUSIONS The quantitative description of the link between risk factors and CVD informs the construction of individualized CVD mitigation strategies, design of primary prevention trials, and assessment of public health impact of risk factor-based interventions.
Collapse
Affiliation(s)
- Michael J Domanski
- Division of Cardiovascular Medicine and Data Science Initiative, University of Maryland School of Medicine and the VA Medical Center, Baltimore, Maryland, USA.
| | - Colin O Wu
- Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Xin Tian
- Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Ahmed A Hasan
- Division of Cardiovascular Medicine and Data Science Initiative, University of Maryland School of Medicine and the VA Medical Center, Baltimore, Maryland, USA; Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
| | - Xiaoyang Ma
- Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Yi Huang
- Division of Cardiovascular Medicine and Data Science Initiative, University of Maryland School of Medicine and the VA Medical Center, Baltimore, Maryland, USA; Department of Mathematics and Statistics, University of Maryland Baltimore County, Baltimore, Maryland, USA
| | - Rui Miao
- Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Jared P Reis
- Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
| | - Sejong Bae
- Division of Preventive Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
| | - Anwar Husain
- Division of Cardiovascular Medicine and Data Science Initiative, University of Maryland School of Medicine and the VA Medical Center, Baltimore, Maryland, USA
| | - David R Jacobs
- Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
| | - Norrina B Allen
- Department of Preventive Medicine, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA
| | - Mei-Ling T Lee
- Department of Epidemiology and Biostatistics, University of Maryland, College Park, Maryland, USA
| | - Charles C Hong
- Division of Cardiovascular Medicine and Data Science Initiative, University of Maryland School of Medicine and the VA Medical Center, Baltimore, Maryland, USA
| | - Michael E Farkouh
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Donald M Lloyd-Jones
- Department of Preventive Medicine, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA
| | - Valentin Fuster
- Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| |
Collapse
|
25
|
Udell JA, Brickman AR, Chu A, Ferreira-Legere LE, Sheth MS, Ko DT, Austin PC, Abdel-Qadir H, Ivers NM, Bhatia RS, Farkouh ME, Stukel TA, Tu JV. Primary Care Clinical Volumes, Cholesterol Testing, and Cardiovascular Outcomes. Can J Cardiol 2023; 39:340-349. [PMID: 36574928 DOI: 10.1016/j.cjca.2022.12.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Revised: 12/07/2022] [Accepted: 12/20/2022] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND It is unknown whether the annual number of primary care physician (PCP) unique outpatient assessments, which we refer to as clinical volume, translates into better cardiovascular preventive care. We examined the relationship between PCP outpatient clinical volumes and cholesterol testing and major adverse cardiovascular event rates among guideline-recommended eligible patients. METHODS This was a retrospective cohort study conducted as part of the Cardiovascular Health in Ambulatory Care Research Team (CANHEART) cohort, a population-based cohort of almost all adult residents of Ontario, Canada, followed from 2008 to 2012. For each clinical volume quintile, we compared cholesterol testing and major adverse cardiovascular events, defined as time to first event of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS The 10,037 PCPs evaluated had an annualized median volume of 2303 clinical encounters (IQR 1292-3680). Among 4,740,380 patients, 84% underwent guideline-concordant cholesterol testing at least once over 5 years, ranging from 73% with the lowest clinical volume quintile physicians to 86% with the highest. After multivariable adjustment, there was a 10.5% relative increase in the probability of cholesterol testing for every doubling of clinical volumes (95% CI 9.7-11.4; P < 0.001). Patients treated by the lowest volume quintile physicians had the highest rate of major adverse cardiovascular outcomes (compared with the highest volume quintile physicians: adjusted HR 1.15, 95% CI 1.10-1.21; P < 0.001). CONCLUSIONS Patients of physicians with the lowest clinical volumes received less frequent cholesterol testing and had the highest rate of incident cardiovascular events. Further research investigating the drivers of this relationship is warranted.
Collapse
Affiliation(s)
- Jacob A Udell
- Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada; Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada; Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
| | - Arielle R Brickman
- Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada; Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada
| | | | | | - Maya S Sheth
- Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - Dennis T Ko
- ICES, Toronto, Ontario, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada; Schulich Heart Centre, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Peter C Austin
- ICES, Toronto, Ontario, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | - Husam Abdel-Qadir
- Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada; Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada; Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | - Noah M Ivers
- Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada; Department of Family Medicine, Women's College Hospital, Toronto, Ontario, Canada
| | - R Sacha Bhatia
- Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada; Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada; Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | - Michael E Farkouh
- Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
| | - Thérèse A Stukel
- ICES, Toronto, Ontario, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | - Jack V Tu
- ICES, Toronto, Ontario, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada; Schulich Heart Centre, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| |
Collapse
|
26
|
Godoy LC, Ko DT, Austin P, Shah B, Qiu F, Sud M, Nicolau JC, Sun L, Fremes SE, Rocha R, Tam D, Humphries K, Lawler PR, Wijeysundera H, Gaudino MF, Farkouh ME. MULTIVESSEL REVASCULARIZATION IN PATIENTS WITH DIABETES AND ACUTE CORONARY SYNDROMES. J Am Coll Cardiol 2023. [DOI: 10.1016/s0735-1097(23)01639-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
|
27
|
Godoy LC, Farkouh ME, Austin PC, Shah BR, Qiu F, Sud M, Wijeysundera HC, Mancini GBJ, Ko DT. Predicting left main stenosis in stable ischemic heart disease using logistic regression and boosted trees. Am Heart J 2023; 256:117-127. [PMID: 36372249 DOI: 10.1016/j.ahj.2022.11.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Revised: 10/27/2022] [Accepted: 11/04/2022] [Indexed: 06/16/2023]
Abstract
BACKGROUND The ISCHEMIA trial showed similar cardiovascular outcomes of an initial conservative strategy as compared with invasive management in patients with stable ischemic heart disease without left main stenosis. We aim to assess the feasibility of predicting significant left main stenosis using extensive clinical, laboratory and non-invasive tests data. METHODS All adult patients who had stress testing prior to undergoing an elective coronary angiography for stable ischemic heart disease in Ontario, Canada, between April 2010 and March 2019, were included. Candidate predictors included comprehensive demographics, comorbidities, laboratory tests, and cardiac stress test data. The outcome was stenosis of 50% or greater in the left main coronary artery. A traditional model (logistic regression) and a machine learning algorithm (boosted trees) were used to build prediction models. RESULTS Among 150,423 patients included (mean age: 64.2 ± 10.6 years; 64.1% males), there were 9,225 (6.1%) with left main stenosis. The final logistic regression model included 24 predictors and 3 interactions, had an optimism-adjusted c-statistic of 0.72 and adequate calibration (optimism-adjusted Integrated Calibration Index 0.0044). These results were consistent in subgroups of males and females, diabetes and non-diabetes, and extent of ischemia. The boosted tree algorithm had similar accuracy, also resulting in a c-statistic of 0.72 and adequate calibration (Integrated Calibration Index 0.0054). CONCLUSIONS In this large population-based study of patients with stable ischemic heart disease using extensive clinical data, only modest prediction of left main coronary artery disease was possible with traditional and machine learning modelling techniques.
Collapse
Affiliation(s)
- Lucas C Godoy
- Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, ON, Canada; Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, Brazil
| | - Michael E Farkouh
- Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, ON, Canada
| | - Peter C Austin
- ICES, Toronto, ON, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, ON, Canada
| | - Baiju R Shah
- ICES, Toronto, ON, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | | | - Maneesh Sud
- ICES, Toronto, ON, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Schulich Heart Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - Harindra C Wijeysundera
- ICES, Toronto, ON, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Schulich Heart Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - G B John Mancini
- Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, BC, Canada
| | - Dennis T Ko
- ICES, Toronto, ON, Canada; Institute of Health Policy Management, and Evaluation, University of Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Schulich Heart Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
| |
Collapse
|
28
|
Peikert A, Claggett BL, Kim K, Udell JA, Joseph J, Desai AS, Farkouh ME, Hegde SM, Hernandez AF, Bhatt DL, Gaziano JM, Talbot HK, Yancy C, Anand I, Mao L, Cooper LS, Solomon SD, Vardeny O. Association of post-vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with high-risk cardiovascular disease: the INVESTED trial. Eur J Heart Fail 2023; 25:299-310. [PMID: 36335639 DOI: 10.1002/ejhf.2716] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Revised: 10/05/2022] [Accepted: 10/07/2022] [Indexed: 11/09/2022] Open
Abstract
AIMS Influenza vaccination is associated with reduced cardiopulmonary morbidity and mortality among patients with heart failure or recent myocardial infarction. The immune response to vaccination frequently results in mild adverse reactions (AR), which leads to vaccine hesitancy. This post hoc analysis explored the association between vaccine-related AR and morbidity and mortality in patients with high-risk cardiovascular disease. METHODS AND RESULTS The INVESTED trial randomized 5260 patients with recent heart failure hospitalization or acute myocardial infarction to high-dose trivalent or standard-dose quadrivalent inactivated influenza vaccine. We examined the association between vaccine-related AR and adverse clinical outcomes across both treatment groups in propensity-adjusted models. Among 5210 participants with available information on post-vaccination symptoms, 1968 participants (37.8%) experienced a vaccine-related AR. Compared to those without AR, post-vaccination AR, most commonly injection site pain (60.3%), were associated with lower risk for the composite of all-cause death or cardiopulmonary hospitalization (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.75-0.92, p < 0.001), cardiopulmonary hospitalizations (HR 0.85 [95% CI 0.76-0.95], p = 0.003), all-cause death (HR 0.77 [95% CI 0.62-0.96], p = 0.02), cardiovascular hospitalizations (HR 0.88 [95% CI 0.78-0.99], p = 0.03) and non-cardiopulmonary hospitalizations (HR 0.80 [95% CI 0.69-0.92], p = 0.003). While mild (76.4%) and moderate (20.6%) AR were most common and together associated with lower risk for the primary outcome (HR 0.81 [95% CI 0.74-0.90], p < 0.001), severe AR (2.9%) were related to increased risk (HR 1.68 [95% CI 1.17-2.42], p = 0.005). CONCLUSION Mild to moderate post-vaccination reactions after influenza vaccine were associated with reduced risk of cardiopulmonary hospitalizations and all-cause mortality in patients with high-risk cardiovascular disease, while severe reactions may indicate increased risk. Mild to moderate AR to influenza vaccination may be a marker of immune response and should not deter future vaccinations.
Collapse
Affiliation(s)
- Alexander Peikert
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Brian L Claggett
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - KyungMann Kim
- Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, USA
| | - Jacob A Udell
- Peter Munk Cardiac Centre, University Health Network and Women's College Hospital, University of Toronto, Toronto, ONT, Canada
| | - Jacob Joseph
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Department of Medicine, Boston, MA, USA
| | - Akshay S Desai
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Michael E Farkouh
- Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, ONT, Canada
| | - Sheila M Hegde
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | | | - Deepak L Bhatt
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - J Michael Gaziano
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Department of Medicine, Boston, MA, USA
| | - H Keipp Talbot
- Department of Medicine, Vanderbilt University, Nashville, TN, USA
| | - Clyde Yancy
- Department of Medicine, Northwestern University, Chicago, IL, USA
| | - Inder Anand
- Department of Medicine, University of Minnesota, Minneapolis VA Health Care System, Minneapolis, MN, USA
| | - Lu Mao
- Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, USA
| | - Lawton S Cooper
- National Heart, Lung, and Blood Institute, Bethesda, MD, USA
| | - Scott D Solomon
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Orly Vardeny
- Department of Medicine, University of Minnesota, Minneapolis VA Health Care System, Minneapolis, MN, USA
| |
Collapse
|
29
|
McKinley EC, Bittner VA, Brown TM, Chen L, Exter J, Farkouh ME, Huang L, Jackson EA, Levitan EB, Orroth KK, Reading SR, Rosenson RS, Safford MM, Woodward M, Muntner P, Colantonio LD. The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD. Cardiovasc Drugs Ther 2023; 37:107-116. [PMID: 34599698 DOI: 10.1007/s10557-021-07268-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/17/2021] [Indexed: 01/14/2023]
Abstract
PURPOSE Adults with atherosclerotic cardiovascular disease (ASCVD) are recommended high-intensity statins, with those at very high risk for recurrent events recommended adding ezetimibe and/or a proprotein convertase subtilisin/kexin type 9 inhibitor if their low-density lipoprotein cholesterol (LDL-C) is ≥70 mg/dL. We estimated the number of recurrent ASCVD events potentially averted if all adults in the United States (US) ≥45 years of age with ASCVD achieved an LDL-C <70 mg/dL. METHODS The number of US adults with ASCVD and LDL-C ≥70 mg/dL was estimated from the National Health and Nutrition Examination Survey 2009-2016 (n = 596). The 10-year cumulative incidence of recurrent ASCVD events was estimated from the REasons for Geographic And Racial Differences in Stroke study (n = 5390), weighted to the US population by age, race, and sex. The ASCVD risk reduction by achieving an LDL-C <70 mg/dL was estimated from meta-analyses of lipid-lowering treatment trials. RESULTS Overall, 14.7 (95% CI, 13.7-15.8) million US adults had ASCVD, of whom 11.6 (95% CI, 10.6-12.5) million had LDL-C ≥70 mg/dL. The 10-year cumulative incidence of ASCVD events was 24.3% (95% CI, 23.2-25.6%). We projected that 2.823 (95% CI, 2.543-3.091) million ASCVD events would occur over 10 years among US adults with ASCVD and LDL-C ≥70 mg/dL. Overall, 0.634 (95% CI, 0.542-0.737) million ASCVD events could potentially be averted if all US adults with ASCVD achieved and maintained LDL-C <70 mg/dL. CONCLUSION A substantial number of recurrent ASCVD events could be averted over 10 years if all US adults with ASCVD achieved, and maintained, an LDL-C <70 mg/dL.
Collapse
Affiliation(s)
- Emily C McKinley
- Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd, RPHB 523B, Birmingham, AL, 35233-0013, USA.
| | - Vera A Bittner
- Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Todd M Brown
- Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Ligong Chen
- Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd, RPHB 523B, Birmingham, AL, 35233-0013, USA
| | | | - Michael E Farkouh
- Peter Munk Cardiac Centre, University of Toronto and Heart and Stroke Richard Lewar Centre of Excellence, Toronto, ON, Canada
| | - Lei Huang
- Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd, RPHB 523B, Birmingham, AL, 35233-0013, USA
| | - Elizabeth A Jackson
- Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Emily B Levitan
- Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd, RPHB 523B, Birmingham, AL, 35233-0013, USA
| | - Kate K Orroth
- Center for Observational Research, Amgen Inc., Thousand Oaks, CA, USA
| | | | - Robert S Rosenson
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Monika M Safford
- Department of Medicine, Weill Cornell Medicine, New York, NY, USA
| | - Mark Woodward
- The George Institute for Global Health, University of New South Wales, Sydney, Australia.,The George Institute for Global Health, School of Public Health, Imperial College London, London, UK
| | - Paul Muntner
- Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd, RPHB 523B, Birmingham, AL, 35233-0013, USA
| | - Lisandro D Colantonio
- Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd, RPHB 523B, Birmingham, AL, 35233-0013, USA
| |
Collapse
|
30
|
Lee DS, Straus SE, Farkouh ME, Austin PC, Taljaard M, Chong A, Fahim C, Poon S, Cram P, Smith S, McKelvie RS, Porepa L, Hartleib M, Mitoff P, Iwanochko RM, MacDougall A, Shadowitz S, Abrams H, Elbarasi E, Fang J, Udell JA, Schull MJ, Mak S, Ross HJ. Trial of an Intervention to Improve Acute Heart Failure Outcomes. N Engl J Med 2023; 388:22-32. [PMID: 36342109 DOI: 10.1056/nejmoa2211680] [Citation(s) in RCA: 47] [Impact Index Per Article: 47.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Patients with acute heart failure are frequently or systematically hospitalized, often because the risk of adverse events is uncertain and the options for rapid follow-up are inadequate. Whether the use of a strategy to support clinicians in making decisions about discharging or admitting patients, coupled with rapid follow-up in an outpatient clinic, would affect outcomes remains uncertain. METHODS In a stepped-wedge, cluster-randomized trial conducted in Ontario, Canada, we randomly assigned 10 hospitals to staggered start dates for one-way crossover from the control phase (usual care) to the intervention phase, which involved the use of a point-of-care algorithm to stratify patients with acute heart failure according to the risk of death. During the intervention phase, low-risk patients were discharged early (in ≤3 days) and received standardized outpatient care, and high-risk patients were admitted to the hospital. The coprimary outcomes were a composite of death from any cause or hospitalization for cardiovascular causes within 30 days after presentation and the composite outcome within 20 months. RESULTS A total of 5452 patients were enrolled in the trial (2972 during the control phase and 2480 during the intervention phase). Within 30 days, death from any cause or hospitalization for cardiovascular causes occurred in 301 patients (12.1%) who were enrolled during the intervention phase and in 430 patients (14.5%) who were enrolled during the control phase (adjusted hazard ratio, 0.88; 95% confidence interval [CI], 0.78 to 0.99; P = 0.04). Within 20 months, the cumulative incidence of primary-outcome events was 54.4% (95% CI, 48.6 to 59.9) among patients who were enrolled during the intervention phase and 56.2% (95% CI, 54.2 to 58.1) among patients who were enrolled during the control phase (adjusted hazard ratio, 0.95; 95% CI, 0.92 to 0.99). Fewer than six deaths or hospitalizations for any cause occurred in low- or intermediate-risk patients before the first outpatient visit within 30 days after discharge. CONCLUSIONS Among patients with acute heart failure who were seeking emergency care, the use of a hospital-based strategy to support clinical decision making and rapid follow-up led to a lower risk of the composite of death from any cause or hospitalization for cardiovascular causes within 30 days than usual care. (Funded by the Ontario SPOR Support Unit and others; COACH ClinicalTrials.gov number, NCT02674438.).
Collapse
Affiliation(s)
- Douglas S Lee
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Sharon E Straus
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Michael E Farkouh
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Peter C Austin
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Monica Taljaard
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Alice Chong
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Christine Fahim
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Stephanie Poon
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Peter Cram
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Stuart Smith
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Robert S McKelvie
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Liane Porepa
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Michael Hartleib
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Peter Mitoff
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Robert M Iwanochko
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Andrea MacDougall
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Steven Shadowitz
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Howard Abrams
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Esam Elbarasi
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Jiming Fang
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Jacob A Udell
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Michael J Schull
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Susanna Mak
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| | - Heather J Ross
- From the University of Toronto (D.S.L., S.E.S., M.E.F., P.C.A., S.P., P.C., R.M.I., S. Shadowitz, H.A., J.A.U., M.J.S., S.M., H.J.R.), the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre, University Health Network (D.S.L., M.E.F., J.A.U., H.J.R.), ICES (formerly the Institute for Clinical Evaluative Sciences) (D.S.L., P.C.A., A.C., P.C., J.F., J.A.U., M.J.S.), St. Michael's Hospital and Li Ka Shing Knowledge Institute, Unity Health (S.E.S., C.F.), the Divisions of Cardiology (S.P.) and General Internal Medicine (S. Shadowitz) and the Department of Emergency Services and Sunnybrook Research Institute (M.J.S.), Sunnybrook Health Sciences Centre, the Division of Cardiology, St. Joseph's Hospital (P.M.), the Division of Cardiology, Toronto Western Hospital (R.M.I.), the Division of General Internal Medicine, Toronto General Hospital (H.A.), the Division of Cardiology, Women's College Hospital (J.A.U.), and the Division of Cardiology, Sinai Health (S.M.), Toronto, the Clinical Epidemiology Program, Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa (M.T.), the Division of Cardiology, London Health Sciences Centre (S. Smith), Western University (S. Smith, R.S.M.), and the Division of Cardiology, St. Joseph's Health Care (R.S.M.), London, the Division of Cardiology, Southlake Regional Health Centre, Newmarket (L.P.), the Division of Cardiology, Peterborough Regional Health Centre, Peterborough (M.H.), the Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay (A.M.), and the Division of Cardiology, William Osler Health System, Brampton (E.E.) - all in Ontario, Canada; and the Department of Medicine, University of Texas Medical Branch, Galveston (P.C.)
| |
Collapse
|
31
|
Sheth MS, Yu B, Chu A, Porter J, Tam DY, Ferreira‐Legere LE, Goodman SG, Farkouh ME, Ko DT, Abdel‐Qadir H, Udell JA. Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study. J Am Heart Assoc 2022; 11:e026553. [PMID: 36515238 PMCID: PMC9798819 DOI: 10.1161/jaha.122.026553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Background The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial decreased major adverse cardiovascular events with very low-dose rivaroxaban and aspirin in patients with coronary artery disease and peripheral artery disease. We examined the eligibility and potential real-world impact of this strategy on the COMPASS-eligible population. Methods and Results COMPASS eligibility criteria were applied to the CANHEART (Cardiovascular Health in Ambulatory Care Research Team) registry, a population-based cohort of Ontario adults. We compared 5-year major adverse cardiovascular events and major bleeding rates stratified by COMPASS eligibility and by clinical risk factors. We applied COMPASS trial rivaroxaban/aspirin arm hazard ratios to estimate the potential impact on the COMPASS-eligible cohort. Among 362 797 patients with coronary artery disease or peripheral artery disease, 38% were deemed eligible, 47% ineligible, and 15% indeterminate. Among eligible patients, a greater number of risk factors was associated with higher rates of cardiovascular outcomes, whereas bleeding rates increased minimally. Over 5 years, applying COMPASS treatment effects to eligible patients resulted in a 2.4% absolute risk reduction of major adverse cardiovascular events and a number needed to treat of 42, and a 1.3% absolute risk increase of major bleeding and number needed to harm (NNH) of 77. Those with at least 2 risk factors had a 3.0% absolute risk reduction of major adverse cardiovascular events (number needed to treat =34) and a 1.6% absolute risk increase of major bleeding (number needed to harm =61). Conclusions Implementation of very-low-dose rivaroxaban therapy would potentially impact ≈$$ \approx $$2 in 5 patients with atherosclerotic disease in Ontario. Eligible individuals with ≥$$ \ge $$2 comorbidities represent a high-risk subgroup that may derive the greatest benefit-to-risk ratio. Selection of patients with high-risk predisposing factors appears appropriate in routine practice.
Collapse
Affiliation(s)
- Maya S. Sheth
- Women’s College Research InstituteTorontoCanada,Dalla Lana School of Public HealthUniversity of TorontoCanada
| | | | | | | | - Derrick Y Tam
- ICESTorontoCanada,Schulich Heart Centre, Sunnybrook Health Sciences CentreTorontoCanada,Institute of Health Policy, Management, and EvaluationUniversity of TorontoCanada
| | | | - Shaun G. Goodman
- Applied Health Research Centre, Li Ka Shing Knowledge InstituteSt Michael’s HospitalTorontoCanada,Department of Medicine, Faculty of MedicineUniversity of TorontoCanada
| | - Michael E. Farkouh
- Applied Health Research Centre, Li Ka Shing Knowledge InstituteSt Michael’s HospitalTorontoCanada,Department of Medicine, Faculty of MedicineUniversity of TorontoCanada,Peter Munk Cardiac CentreUniversity Health NetworkTorontoCanada
| | - Dennis T. Ko
- ICESTorontoCanada,Schulich Heart Centre, Sunnybrook Health Sciences CentreTorontoCanada,Institute of Health Policy, Management, and EvaluationUniversity of TorontoCanada
| | - Husam Abdel‐Qadir
- Women’s College Research InstituteTorontoCanada,ICESTorontoCanada,Institute of Health Policy, Management, and EvaluationUniversity of TorontoCanada,Department of Medicine, Faculty of MedicineUniversity of TorontoCanada,Peter Munk Cardiac CentreUniversity Health NetworkTorontoCanada,Cardiovascular Division, Department of MedicineWomen’s College HospitalTorontoCanada
| | - Jacob A. Udell
- Women’s College Research InstituteTorontoCanada,ICESTorontoCanada,Institute of Health Policy, Management, and EvaluationUniversity of TorontoCanada,Applied Health Research Centre, Li Ka Shing Knowledge InstituteSt Michael’s HospitalTorontoCanada,Department of Medicine, Faculty of MedicineUniversity of TorontoCanada,Peter Munk Cardiac CentreUniversity Health NetworkTorontoCanada,Cardiovascular Division, Department of MedicineWomen’s College HospitalTorontoCanada
| |
Collapse
|
32
|
Eikelboom JW, Jolly SS, Belley-Cote EP, Whitlock RP, Rangarajan S, Xu L, Heenan L, Bangdiwala SI, Luz Diaz M, Diaz R, Yusufali A, Kumar Sharma S, Tarhuni WM, Hassany M, Avezum A, Harper W, Wasserman S, Almas A, Drapkina O, Felix C, Lopes RD, Berwanger O, Lopez-Jaramillo P, Anand SS, Bosch J, Choudhri S, Farkouh ME, Loeb M, Yusuf S. Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respir Med 2022; 10:1169-1177. [PMID: 36228641 PMCID: PMC9635892 DOI: 10.1016/s2213-2600(22)00298-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 08/03/2022] [Accepted: 08/04/2022] [Indexed: 12/14/2022]
Abstract
BACKGROUND COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19. METHODS The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patients aged at least 18 years with symptomatic, laboratory confirmed COVID-19 who were within 72 h of hospitalisation or worsening clinically if already hospitalised were randomly assigned (1:1) to receive colchicine 1·2 mg followed by 0·6 mg 2 h later and then 0·6 mg twice daily for 28 days versus usual care; and in a second (1:1) randomisation, to the combination of rivaroxaban 2·5 mg twice daily plus aspirin 100 mg once daily for 28 days versus usual care. Investigators and patients were not masked to treatment allocation. The primary outcome, assessed at 45 days in the intention-to-treat population, for the colchicine randomisation was the composite of the need for high-flow oxygen, mechanical ventilation, or death; and for the rivaroxaban plus aspirin randomisation was the composite of major thrombosis (myocardial infarction, stroke, acute limb ischaemia, or pulmonary embolism), the need for high-flow oxygen, mechanical ventilation, or death. The trial is registered at www. CLINICALTRIALS gov, NCT04324463 and is ongoing. FINDINGS Between Oct 2, 2020, and Feb 10, 2022, at 62 sites in 11 countries, 2749 patients were randomly assigned to colchicine or control and the combination of rivaroxaban and aspirin or to the control. 2611 patients were included in the analysis of colchicine (n=1304) versus control (n=1307); 2119 patients were included in the analysis of rivaroxaban and aspirin (n=1063) versus control (n=1056). Follow-up was more than 98% complete. Overall, 368 (28·2%) of 1304 patients allocated to colchicine and 356 (27·2%) of 1307 allocated to control had a primary outcome (hazard ratio [HR] 1·04, 95% CI 0·90-1·21, p=0·58); and 281 (26·4%) of 1063 patients allocated to the combination of rivaroxaban and aspirin and 300 (28·4%) of 1056 allocated to control had a primary outcome (HR 0·92, 95% CI 0·78-1·09, p=0·32). Results were consistent in subgroups defined by vaccination status, disease severity at baseline, and timing of randomisation in relation to onset of symptoms. There was no increase in the number of patients who had at least one serious adverse event for colchicine versus control groups (87 [6·7%] of 1304 vs 90 [6·9%] of 1307) or with rivaroxaban and aspirin versus control groups (85 [8·0%] vs 91 [8·6%]). Among patients assigned to colchicine, 8 (0·61%) had adverse events that led to discontinuation of study drug, mostly gastrointestinal in nature. 17 (1·6%) patients assigned to the combination of rivaroxaban and aspirin had bleeding compared with seven (0·66%) of those allocated to control (p=0·042); the number of serious bleeding events was two (0·19%) versus six (0·57%), respectively (p=0·18). No patients assigned to rivaroxaban and aspirin had serious adverse events that led to discontinuation of study drug. INTERPRETATION Among patients hospitalised with COVID-19, neither colchicine nor the combination of rivaroxaban and aspirin prevent disease progression or death. FUNDING Canadian Institutes for Health Research, Bayer, Population Health Research Institute, Hamilton Health Sciences Research Institute, Thistledown Foundation. TRANSLATIONS For the Portuguese, Russian and Spanish translations of the abstract see Supplementary Materials section.
Collapse
Affiliation(s)
- John W Eikelboom
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada,Department of Medicine, McMaster University, Hamilton, ON, Canada,Correspondence to: Prof John W Eikelboom, Population Health Research Institute, Hamilton, ON L8L 2X2, Canada
| | - Sanjit S Jolly
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada,Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Emilie P Belley-Cote
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada,Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Richard P Whitlock
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada,Department of Surgery, McMaster University, Hamilton, ON, Canada
| | - Sumathy Rangarajan
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada
| | - Lizhen Xu
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada
| | - Laura Heenan
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada
| | - Shrikant I Bangdiwala
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada
| | - Maria Luz Diaz
- Estudios Clínicos Latino América, Instituto Cardiovascular de Rosario, Rosario, Argentina
| | - Rafael Diaz
- Estudios Clínicos Latino América, Instituto Cardiovascular de Rosario, Rosario, Argentina
| | - Afzalhussein Yusufali
- Hatta Hospital, Dubai Medical College, Dubai Health Authority, Dubai, United Arab Emirates
| | | | - Wadea M Tarhuni
- Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada,Department of Medicine, Western University, Clinical Skills Building London, ON, Canada,Windsor Cardiac Centre, Windsor, ON, Canada
| | - Mohamed Hassany
- National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
| | - Alvaro Avezum
- International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil
| | - William Harper
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada
| | - Sean Wasserman
- Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa,Division of Infectious Diseases and HIV Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa
| | - Aysha Almas
- Section of Internal Medicine, Department of Medicine, Aga Khan University, Karachi, Pakistan
| | - Oxana Drapkina
- National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
| | - Camilo Felix
- Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Ecuador
| | - Renato D Lopes
- Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, NC, USA
| | | | | | - Sonia S Anand
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada,Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Jackie Bosch
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada,School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada
| | | | - Michael E Farkouh
- Peter Munk Cardiac Centre, University of Toronto, Toronto, ON, Canada
| | - Mark Loeb
- Departments of Pathology and Molecular Medicine and Health Evidence Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Salim Yusuf
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada,Department of Surgery, McMaster University, Hamilton, ON, Canada
| |
Collapse
|
33
|
Eikelboom JW, Jolly SS, Belley-Cote EP, Whitlock RP, Rangarajan S, Xu L, Heenan L, Bangdiwala SI, Tarhuni WM, Hassany M, Kontsevaya A, Harper W, Sharma SK, Lopez-Jaramillo P, Dans AL, Palileo-Villanueva LM, Avezum A, Pais P, Xavier D, Felix C, Yusufali A, Lopes RD, Berwanger O, Ali Z, Wasserman S, Anand SS, Bosch J, Choudhri S, Farkouh ME, Loeb M, Yusuf S. Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respir Med 2022; 10:1160-1168. [PMID: 36228639 PMCID: PMC9635862 DOI: 10.1016/s2213-2600(22)00299-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 07/28/2022] [Accepted: 08/02/2022] [Indexed: 02/07/2023]
Abstract
BACKGROUND The large number of patients worldwide infected with the SARS-CoV-2 virus has overwhelmed health-care systems globally. The Anti-Coronavirus Therapies (ACT) outpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with aspirin for prevention of disease progression in community patients with COVID-19. METHODS The ACT outpatient, open-label, 2 × 2 factorial, randomised, controlled trial, was done at 48 clinical sites in 11 countries. Patients in the community aged 30 years and older with symptomatic, laboratory confirmed COVID-19 who were within 7 days of diagnosis and at high risk of disease progression were randomly assigned (1:1) to receive colchicine 0·6 mg twice daily for 3 days and then 0·6 mg once daily for 25 days versus usual care, and in a second (1:1) randomisation to receive aspirin 100 mg once daily for 28 days versus usual care. Investigators and patients were not masked to treatment allocation. The primary outcome was assessed at 45 days in the intention-to-treat population; for the colchicine randomisation it was hospitalisation or death, and for the aspirin randomisation it was major thrombosis, hospitalisation, or death. The ACT outpatient trial is registered at ClinicalTrials.gov, NCT04324463 and is ongoing. FINDINGS Between Aug 27, 2020, and Feb 10, 2022, 3917 patients were randomly assigned to colchicine or control and to aspirin or control; after excluding 36 patients due to administrative reasons 3881 individuals were included in the analysis (n=1939 colchicine vs n=1942 control; n=1945 aspirin vs 1936 control). Follow-up was more than 99% complete. Overall event rates were 5 (0·1%) of 3881 for major thrombosis, 123 (3·2%) of 3881 for hospitalisation, and 23 (0·6%) of 3881 for death; 66 (3·4%) of 1939 patients allocated to colchicine and 65 (3·3%) of 1942 patients allocated to control experienced hospitalisation or death (hazard ratio [HR] 1·02, 95% CI 0·72-1·43, p=0·93); and 59 (3·0%) of 1945 of patients allocated to aspirin and 73 (3·8%) of 1936 patients allocated to control experienced major thrombosis, hospitalisation, or death (HR 0·80, 95% CI 0·57-1·13, p=0·21). Results for the primary outcome were consistent in all prespecified subgroups, including according to baseline vaccination status, timing of randomisation in relation to onset of symptoms (post-hoc analysis), and timing of enrolment according to the phase of the pandemic (post-hoc analysis). There were more serious adverse events with colchicine than with control (34 patients [1·8%] of 1939 vs 27 [1·4%] of 1942) but none in either group that led to discontinuation of study interventions. There was no increase in serious adverse events with aspirin versus control (31 [1·6%] vs 31 [1·6%]) and none that led to discontinuation of study interventions. INTERPRETATION The results provide no support for the use of colchicine or aspirin to prevent disease progression or death in outpatients with COVID-19. FUNDING Canadian Institutes for Health Research, Bayer, Population Health Research Institute, Hamilton Health Sciences Research Institute, and Thistledown Foundation. TRANSLATIONS For the Portuguese, Russian and Spanish translations of the abstract see Supplementary Materials section.
Collapse
Affiliation(s)
- John W Eikelboom
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.
| | - Sanjit S Jolly
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada,Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Emilie P Belley-Cote
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada,Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Richard P Whitlock
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada,Department of Surgery, McMaster University, Hamilton, ON, Canada
| | - Sumathy Rangarajan
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada
| | - Lizhen Xu
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada
| | - Laura Heenan
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada
| | - Shrikant I Bangdiwala
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada,Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Wadea M Tarhuni
- Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada,Department of Medicine, Western University, Clinical Skills Building London, ON, Canada,Windsor Cardiac Centre, Windsor, ON, Canada
| | - Mohamed Hassany
- National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
| | - Anna Kontsevaya
- National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
| | - William Harper
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| | | | | | - Antonio L Dans
- UP College of Medicine, University of the Philippines Manila, Manila, Philippines
| | | | - Alvaro Avezum
- International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil
| | - Prem Pais
- St John's Research Institute, Bangalore, India
| | - Denis Xavier
- St John's Medical College, St John's Research Institute, Bangalore, India
| | - Camilo Felix
- Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Ecuador
| | - Afzalhussein Yusufali
- Hatta Hospital, Dubai Medical College, Dubai Health Authority, Dubai, United Arab Emirates
| | - Renato D Lopes
- Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, NC, USA
| | | | - Zeeshan Ali
- Jinnah Sindh Medical University and Jinnah Postgraduate Medical Center, Karachi, Pakistan
| | - Sean Wasserman
- Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa,Division of Infectious Diseases and HIV Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa
| | - Sonia S Anand
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada,Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Jackie Bosch
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada,School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada
| | | | - Michael E Farkouh
- Peter Munk Cardiac Centre, University of Toronto, Toronto, ON, Canada
| | - Mark Loeb
- Departments of Pathology and Molecular Medicine and Health Evidence Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Salim Yusuf
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada,Department of Medicine, McMaster University, Hamilton, ON, Canada
| |
Collapse
|
34
|
Mathew RO, Sidhu MS, Rihal CS, Lennon R, El-Hajjar M, Yager N, Lyubarova R, Abdul-Nour K, Weitz S, O'Cochlain DF, Murthy V, Levisay J, Marzo K, Graham J, Dzavik V, So D, Goodman S, Rosenberg YD, Pereira N, Farkouh ME. Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y 12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study. Cardiovasc Drugs Ther 2022:10.1007/s10557-022-07392-2. [PMID: 36445624 PMCID: PMC10225474 DOI: 10.1007/s10557-022-07392-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/11/2022] [Indexed: 11/30/2022]
Abstract
PURPOSE Chronic kidney disease (CKD) is a risk factor for ischemic and bleeding events with dual antiplatelet therapy after percutaneous coronary intervention (PCI). Whether the presence of CYP2C19 loss of function (LOF) alleles modifies this risk, and whether a genotype-guided (GG) escalation of P2Y12 inhibitor therapy post PCI is safe in this population is unclear. METHODS This was a post hoc analysis of randomized patients in TAILOR PCI. Patients were divided into two groups based on estimated glomerular filtration rate (eGFR) threshold of < 60 ml/min/1.73 m2 for CKD (n = 539) and non-CKD (n = 4276). The aggregate of cardiovascular death, stroke, myocardial infarction, stent thrombosis, and severe recurrent coronary ischemia at 12-months post-PCI was assessed as the primary endpoint. Secondary endpoint was major or minor bleeding. RESULTS Mean (standard deviation) eGFR among patients with CKD was 49.5 (8.4) ml/min/1.72 m2. Among all patients, there was no significant interaction between randomized strategy and CKD status for any endpoint. Among LOF carriers, the interaction between randomized strategy and CKD status on composite ischemic outcome was not significant (p = 0.2). GG strategy was not associated with an increased risk of bleeding in either CKD group. CONCLUSIONS In this exploratory analysis, escalation of P2Y12 inhibitor therapy following a GG strategy did not reduce the primary outcome in CKD. However, P2Y12 inhibitor escalation following a GG strategy was not associated with increased bleeding risk in CKD. Larger studies in CKD are needed. CLINICAL TRIAL REGISTRATION https://clinicaltrials.gov/ct2/show/NCT01742117?term=TAILOR-PCI&draw=2&rank=1 . NCT01742117.
Collapse
Affiliation(s)
- Roy O Mathew
- Department of Medicine, Loma Linda VA Health Care System, 11201 Benton Street, Loma Linda, CA, 92357, USA.
| | - Mandeep S Sidhu
- Department of Medicine, Albany Medical College, 43 New Scotland Avenue Albany, Schenectady, NY, 12208, USA.
| | | | - Ryan Lennon
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA
| | - Mohammed El-Hajjar
- Department of Medicine, Albany Medical College, 43 New Scotland Avenue Albany, Schenectady, NY, 12208, USA
| | - Neil Yager
- Department of Medicine, Albany Medical College, 43 New Scotland Avenue Albany, Schenectady, NY, 12208, USA
| | - Radmila Lyubarova
- Department of Medicine, Albany Medical College, 43 New Scotland Avenue Albany, Schenectady, NY, 12208, USA
| | | | - Steven Weitz
- Cardiology Associates of Schenectady, Schenectady, NY, USA
| | | | - Vishakantha Murthy
- Department of Endocrine and Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
| | - Justin Levisay
- Department of Medicine, North Shore University Health System, Evanston, IL, USA
| | - Kevin Marzo
- Department of Medicine, Winthrop University Hospital, Mineola, NY, USA
| | - John Graham
- Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada
| | - Vlad Dzavik
- Department of Medicine, University Health Network-Toronto General Hospital, Toronto, ON, Canada
| | - Derek So
- Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada
| | - Shaun Goodman
- Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada
| | | | | | - Michael E Farkouh
- Department of Medicine, University Health Network-Toronto General Hospital, Toronto, ON, Canada
| |
Collapse
|
35
|
Patel KV, Khan MS, Segar MW, Bahnson JL, Garcia KR, Clark JM, Balasubramanyam A, Bertoni AG, Vaduganathan M, Farkouh ME, Januzzi JL, Verma S, Espeland M, Pandey A. Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trial. Eur J Heart Fail 2022; 24:2037-2047. [PMID: 36280384 DOI: 10.1002/ejhf.2723] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 09/19/2022] [Accepted: 10/18/2022] [Indexed: 01/18/2023] Open
Abstract
AIMS To evaluate the contribution of baseline and longitudinal changes in cardiometabolic health (CMH) towards heart failure (HF) risk among adults with type 2 diabetes (T2D). METHODS AND RESULTS Participants of the Look AHEAD trial with T2D and without prevalent HF were included. Adjusted Cox models were used to create a CMH score incorporating target levels of parameters weighted based on relative risk for HF. The associations of baseline and changes in the CMH score with risk of overall HF, HF with preserved (HFpEF) and reduced ejection fraction (HFrEF) were assessed using Cox models. Among the 5080 participants, 257 incident HF events occurred over 12.4 years of follow-up. The CMH score included 2 points each for target levels of waist circumference, glomerular filtration rate, urine albumin-to-creatinine ratio, and 1 point each for blood pressure and glycated haemoglobin at target. High baseline CMH score (6-8) was significantly associated with lower overall HF risk (adjusted hazard ratio [HR], ref = low score (0-3): 0.31, 95% confidence interval [CI] 0.21-0.47) with similar associations observed for HFpEF and HFrEF. Improvement in CMH was significantly associated with lower risk of overall HF (adjusted HR per 1-unit increase in score at 4 years: 0.80, 95% CI 0.70-0.91). In the ACCORD validation cohort, the baseline CMH score performed well for predicting HF risk with adequate discrimination (C-index 0.70), calibration (chi-square 5.53, p = 0.70), and risk stratification (adjusted HR [high (6-8) vs. low score (0-3)]: 0.35, 95% CI 0.26-0.46). In the Look AHEAD subgroup with available biomarker data, incorporating N-terminal pro-B-type natriuretic peptide to the baseline CMH score improved model discrimination (C-index 0.79) and risk stratification (adjusted HR [high (8-10) vs. low score (0-4)]: 0.18, 95% CI 0.09-0.35). CONCLUSIONS Achieving target levels of more CMH parameters at baseline and sustained improvements were associated with lower HF risk in T2D.
Collapse
Affiliation(s)
- Kershaw V Patel
- Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA
| | - Muhammad Shahzeb Khan
- Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA
| | - Matthew W Segar
- Department of Cardiology, Texas Heart Institute, Houston, Texas, USA
| | - Judy L Bahnson
- Department of Biostatistical Sciences, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA
| | - Katelyn R Garcia
- Department of Biostatistical Sciences, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA
| | - Jeanne M Clark
- Division of General Internal Medicine, Department of Medicine, The Johns Hopkins School of Medicine, Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
| | - Ashok Balasubramanyam
- Section of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA
| | - Alain G Bertoni
- Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
| | - Muthiah Vaduganathan
- Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Michael E Farkouh
- Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada
| | - James L Januzzi
- Massachusetts General Hospital, Harvard Medical School, Baim Institute for Clinical Research, Boston, Massachusetts, USA
| | - Subodh Verma
- Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Mark Espeland
- Department of Biostatistical Sciences, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA
| | - Ambarish Pandey
- Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| |
Collapse
|
36
|
Farkouh ME, Mathew V. Angiography-Based Measurement of Myocardial Ischemia. J Am Coll Cardiol 2022; 80:2102-2103. [DOI: 10.1016/j.jacc.2022.10.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Accepted: 10/17/2022] [Indexed: 11/22/2022]
|
37
|
Sakhuja S, Bittner VA, Brown TM, Farkouh ME, Levitan EB, Rosenson R, Safford MM, Muntner P, Chen L, Sun R, Noshad S, Dhalwani N, Woodward M, Colantonio LD. Recurrent atherosclerotic cardiovascular disease events preventable with guideline recommended lipid-lowering treatment following myocardial infarction. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The 2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol guideline provides recommendations for lipid-lowering therapy (LLT) including statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) to prevent recurrent atherosclerotic cardiovascular disease (ASCVD) events in adults with established ASCVD. Many adults with ASCVD who are recommended to take statins, ezetimibe and/or PCSK9i do not receive these medications.
Purpose
To estimate the number of recurrent ASCVD events potentially prevented by population-wide use of guideline recommended LLT following a myocardial infarction (MI).
Methods
We simulated the population-wide impact of receipt of 2018 AHA/ACC cholesterol guideline recommended LLT over 3 and 5 years among US adults with government health insurance through Medicare or commercial health insurance following hospital discharge for MI. We used data from patients with an MI hospitalization in 2018–2019 to estimate the percentage receiving guideline recommended LLT defined by having the medications available to take in the 30 days after their discharge date. We used data from patients with an MI hospitalization in 2013–2016 to estimate the 3 and 5-year cumulative incidence of recurrent ASCVD events (i.e., MI, coronary revascularization or ischemic stroke). The reduction in ASCVD events associated with guideline recommended LLT was estimated from a meta-analysis by the Cholesterol-Lowering Treatment Trialists Collaboration. We conducted a sensitivity analysis estimating the number and percentage of ASCVD events prevented if LLT recommendations from the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) cholesterol guideline were followed. We repeated all analyses with recurrent coronary heart disease (i.e., MI or coronary revascularization) and ischemic stroke events as separate outcomes.
Results
Among 279,395 adults with an MI hospitalization in 2018–2019 (mean age 75 years, 54% men, mean low-density lipoprotein cholesterol 92 mg/dL), 27% were receiving guideline recommended LLT. With current lipid-lowering medication use, we estimated that 70,698 (95% CI: 70,311–71,077) and 89,255 (95% CI: 88,841–89,730) ASCVD events would occur in 3 and 5 years, respectively, after MI hospital discharge (Table, top panel). If all patients were to receive 2018 AHA/ACC guideline recommended LLT, the number of ASCVD events was estimated to be reduced by 21.6%, representing 15,264 (95% CI: 14,451–16,679) events prevented over 3 years and 19,271 (95% CI: 18,245–21,055) events prevented over 5 years. A higher number of recurrent ASCVD events were estimated to be averted following the LLT recommendations of the 2019 ESC/EAS cholesterol guideline (Table, bottom panel).
Conclusions
Population-wide implementation of guideline recommended LLT in adults with an MI hospitalization could prevent a substantial number of recurrent ASCVD events.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Amgen Inc.
Collapse
Affiliation(s)
- S Sakhuja
- University of Alabama Birmingham, School of Public Health , Birmingham , United States of America
| | - V A Bittner
- University of Alabama Birmingham, Department of Medicine, Division of Cardiovascular Disease , Birmingham , United States of America
| | - T M Brown
- University of Alabama Birmingham, Department of Medicine, Division of Cardiovascular Disease , Birmingham , United States of America
| | | | - E B Levitan
- University of Alabama Birmingham, School of Public Health , Birmingham , United States of America
| | - R Rosenson
- Icahn School of Medicine at Mount Sinai, Mount Sinai Heart , New York , United States of America
| | - M M Safford
- Weill Cornell Medicine , New York , United States of America
| | - P Muntner
- University of Alabama Birmingham, School of Public Health , Birmingham , United States of America
| | - L Chen
- University of Alabama Birmingham, School of Public Health , Birmingham , United States of America
| | - R Sun
- University of Alabama Birmingham, School of Public Health , Birmingham , United States of America
| | - S Noshad
- Amgen Inc. , Thousand Oaks , United States of America
| | - N Dhalwani
- Amgen Inc. , Thousand Oaks , United States of America
| | - M Woodward
- Imperial College London, The George Institute for Global Health , London , United Kingdom
| | - L D Colantonio
- University of Alabama Birmingham, School of Public Health , Birmingham , United States of America
| |
Collapse
|
38
|
Patel S, Thompson W, Sivaswamy A, Khan A, Ferreira-Legere L, Lee DS, Abdel-Qadir H, Jackevicius C, Goodman S, Farkouh ME, Tu K, Kapral MK, Wijeysundera HC, Tam D, Austin PC, Fang J, Ko DT, Udell JA. Development and validation of a model to categorize cardiovascular cause of death using health administrative data. Am Heart J Plus 2022; 22:100207. [PMID: 38558908 PMCID: PMC10978408 DOI: 10.1016/j.ahjo.2022.100207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Revised: 09/12/2022] [Accepted: 09/13/2022] [Indexed: 04/04/2024]
Abstract
Study objective Develop and evaluate a model that uses health administrative data to categorize cardiovascular (CV) cause of death (COD). Design Population-based cohort. Setting Ontario, Canada. Participants Decedents ≥ 40 years with known COD between 2008 and 2015 in the CANHEART cohort, split into derivation (2008 to 2012; n = 363,778) and validation (2013 to 2015; n = 239,672) cohorts. Main outcome measures Model performance. COD was categorized as CV or non-CV with ICD-10 codes as the gold standard. We developed a logistic regression model that uses routinely collected healthcare administrative to categorize CV versus non-CV COD. We assessed model discrimination and calibration in the validation cohort. Results The strongest predictors for CV COD were history of stroke, history of myocardial infarction, history of heart failure, and CV hospitalization one month before death. In the validation cohort, the c-statistic was 0.80, the sensitivity 0.75 (95 % CI 0.74 to 0.75) and the specificity 0.71 (95 % CI 0.70 to 0.71). In the primary prevention validation sub-cohort, the c-statistic was 0.81, the sensitivity 0.71 (95 % CI 0.70 to 0.71) and the specificity 0.75 (95 % CI 0.75 to 0.75) while in the secondary prevention sub-cohort the c-statistic was 0.74, the sensitivity 0.81 (95 % CI 0.81 to 0.82) and the specificity 0.54 (95 % CI 0.53 to 0.54). Conclusion Modelling approaches using health administrative data show potential in categorizing CV COD, though further work is necessary before this approach is employed in clinical studies.
Collapse
Affiliation(s)
- Sagar Patel
- Faculty of Medicine, University of Toronto, Toronto, Canada
| | - Wade Thompson
- Women's College Research Institute, Toronto, Canada
- ICES, Toronto, Canada
- Research Unit of General Practice, University of Southern Denmark, Odense, Denmark
- Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Canada
| | | | | | | | - Douglas S. Lee
- ICES, Toronto, Canada
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada
- Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
- Peter Munk Cardiac Centre, University Health Network, Toronto, Canada
| | - Husam Abdel-Qadir
- ICES, Toronto, Canada
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada
- Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
- Peter Munk Cardiac Centre, University Health Network, Toronto, Canada
- Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, Canada
| | - Cynthia Jackevicius
- ICES, Toronto, Canada
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada
- Western University of Health Sciences, Pomona, CA, United States of America
| | - Shaun Goodman
- Western University of Health Sciences, Pomona, CA, United States of America
- Division of Cardiology, St. Michael's Hospital, Toronto, Canada
- Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada
| | - Michael E. Farkouh
- Peter Munk Cardiac Centre, University Health Network, Toronto, Canada
- Heart and Stroke/Richard Lewar Centre of Excellence, University of Toronto, Toronto, Canada
| | - Karen Tu
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada
- North York General Hospital, Department of Family and Community Medicine, University of Toronto, Toronto, Canada
- Toronto Western Hospital Family Health Team, University Health Network, Toronto, Canada
| | - Moira K. Kapral
- ICES, Toronto, Canada
- Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
| | - Harindra C. Wijeysundera
- ICES, Toronto, Canada
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada
- Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
- Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Derrick Tam
- Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
| | - Peter C. Austin
- ICES, Toronto, Canada
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada
| | | | - Dennis T. Ko
- ICES, Toronto, Canada
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada
- Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
- Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Jacob A. Udell
- ICES, Toronto, Canada
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada
- Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
- Peter Munk Cardiac Centre, University Health Network, Toronto, Canada
- Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, Canada
| |
Collapse
|
39
|
Lamas GA, Anstrom KJ, Navas-Acien A, Boineau R, Kim H, Rosenberg Y, Stylianou M, Jones TLZ, Joubert BR, Santella RM, Escolar E, Aude YW, Fonseca V, Elliott T, Lewis EF, Farkouh ME, Nathan DM, Mon AC, Gosnell L, Newman JD, Mark DB. The trial to assess chelation therapy 2 (TACT2): Rationale and design. Am Heart J 2022; 252:1-11. [PMID: 35598636 PMCID: PMC9434822 DOI: 10.1016/j.ahj.2022.05.013] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 05/10/2022] [Accepted: 05/17/2022] [Indexed: 05/03/2023]
Abstract
BACKGROUND Intravenous edetate disodium-based infusions reduced cardiovascular events in a prior clinical trial. The Trial to Assess Chelation Therapy 2 (TACT2) will replicate the initial study design. METHODS TACT2 is an NIH-sponsored, randomized, 2x2 factorial, double masked, placebo-controlled, multicenter clinical trial testing 40 weekly infusions of a multi-component edetate disodium (disodium ethylenediamine tetra-acetic acid, or Na2EDTA)-based chelation solution and twice daily oral, high-dose multivitamin and mineral supplements in patients with diabetes and a prior myocardial infarction (MI). TACT2 completed enrollment of 1000 subjects in December 2020, and infusions in December 2021. Subjects are followed for 2.5 to 5 years. The primary endpoint is time to first occurrence of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina. The trial has >;85% power to detect a 30% relative reduction in the primary endpoint. TACT2 also includes a Trace Metals and Biorepository Core Lab, to test whether benefits of treatment, if present, are due to chelation of lead and cadmium from patients. Design features of TACT2 were chosen to replicate selected features of the first TACT, which demonstrated a significant reduction in cardiovascular outcomes in the EDTA chelation arm compared with placebo among patients with a prior MI, with the largest effect in patients with diabetes. RESULTS Results are expected in 2024. CONCLUSION TACT2 may provide definitive evidence of the benefit of edetate disodiumbased chelation on cardiovascular outcomes, as well as the clinical importance of longitudinal changes in toxic metal levels of participants.
Collapse
Affiliation(s)
- Gervasio A Lamas
- Division of Cardiology, Mount Sinai Medical Center, Miami Beach, FL, USA.
| | - Kevin J Anstrom
- Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA
| | - Ana Navas-Acien
- Columbia University Mailman School of Public Health, New York, NY, USA
| | - Robin Boineau
- National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, MD, USA
| | - Hwasoon Kim
- Duke Clinical Research Institute, Duke University, Durham, NC, USA
| | - Yves Rosenberg
- National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
| | - Mario Stylianou
- National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
| | - Teresa L Z Jones
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Bonnie R Joubert
- National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC, USA
| | - Regina M Santella
- Columbia University Mailman School of Public Health, New York, NY, USA
| | - Esteban Escolar
- Division of Cardiology, Mount Sinai Medical Center, Miami Beach, FL, USA
| | - Y Wady Aude
- Heart and Vascular Specialists of South Texas, McAllen, TX, USA
| | - Vivian Fonseca
- Tulane University School of Medicine, New Orleans, LA, USA
| | | | - Eldrin F Lewis
- Stanford University School of Medicine, Palo Alto, CA, USA
| | | | - David M Nathan
- Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Ana C Mon
- Division of Cardiology, Mount Sinai Medical Center, Miami Beach, FL, USA
| | - Leigh Gosnell
- Duke Clinical Research Institute, Duke University, Durham, NC, USA
| | | | - Daniel B Mark
- Duke Clinical Research Institute, Duke University, Durham, NC, USA
| |
Collapse
|
40
|
Scudeler TL, Farkouh ME, Hueb W, Rezende PC, Campolina AG, Martins EB, Godoy LC, Soares PR, Ramires JAF, Kalil Filho R. Coronary atherosclerotic burden assessed by SYNTAX scores and outcomes in surgical, percutaneous or medical strategies: a retrospective cohort study. BMJ Open 2022; 12:e062378. [PMID: 36137633 PMCID: PMC9511539 DOI: 10.1136/bmjopen-2022-062378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION Coronary atherosclerotic burden and SYNTAX Score (SS) are predictors of cardiovascular events. OBJECTIVES To investigate the value of SYNTAX scores (SS, SYNTAX Score II (SSII) and residual SYNTAX Score (rSS)) for predicting cardiovascular events in patients with coronary artery disease (CAD). DESIGN Retrospective cohort study. SETTING Single tertiary centre. PARTICIPANTS Medicine, Angioplasty or Surgery Study database patients with stable multivessel CAD and preserved ejection fraction. INTERVENTIONS Patients with CAD undergoing coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) or medical treatment (MT) alone from January 2002 to December 2015. PRIMARY AND SECONDARY OUTCOMES Primary: 5-year all-cause mortality. Secondary: composite of all-cause death, myocardial infarction, stroke and subsequent coronary revascularisation at 5 years. RESULTS A total of 1719 patients underwent PCI (n=573), CABG (n=572) or MT (n=574) alone. The SS was not considered an independent predictor of 5-year mortality in the PCI (low, intermediate and high SS at 6.5%, 6.8% and 4.3%, respectively, p=0.745), CABG (low, intermediate and high SS at 5.7%, 8.0% and 12.1%, respectively, p=0.194) and MT (low, intermediate and high SS at 6.8%, 6.9% and 6.5%, respectively, p=0.993) cohorts. The SSII (low, intermediate and high SSII at 3.6% vs 7.9% vs 10.5%, respectively, p<0.001) was associated with a higher mortality risk in the overall population. Within each treatment strategy, SSII was associated with a significant 5-year mortality rate, especially in CABG patients with higher SSII (low, intermediate and high SSII at 1.8%, 9.7% and 10.0%, respectively, p=0.004) and in MT patients with high SSII (low, intermediate and high SSII at 5.0%, 4.7% and 10.8%, respectively, p=0.031). SSII demonstrated a better predictive accuracy for mortality compared with SS and rSS (c-index=0.62). CONCLUSIONS Coronary atherosclerotic burden alone was not associated with significantly increased risk of all-cause mortality. The SSII better discriminates the risk of death. TRIAL REGISTRATION NUMBER ISRCTN66068876.
Collapse
Affiliation(s)
- Thiago Luis Scudeler
- Department of Atherosclerosis, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
| | - Michael E Farkouh
- Heart and Stroke/Richard Lewar Centres of Excellence in Cardiovascular Research, Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada
| | - Whady Hueb
- Department of Atherosclerosis, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
| | - Paulo C Rezende
- Department of Atherosclerosis, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
| | - Alessandro G Campolina
- Center for Translational Research in Oncology, Instituto do Câncer Doutor Arnaldo Vieira de Carvalho, São Paulo, São Paulo, Brazil
| | - Eduardo Bello Martins
- Department of Atherosclerosis, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
| | - Lucas C Godoy
- Heart and Stroke/Richard Lewar Centres of Excellence in Cardiovascular Research, Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada
| | - Paulo Rogério Soares
- Department of Atherosclerosis, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
| | - Jose A F Ramires
- Department of Atherosclerosis, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
| | - Roberto Kalil Filho
- Department of Atherosclerosis, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
| |
Collapse
|
41
|
Gaudino M, Farkouh ME, Stone GW. Left main revascularization: breaking through the sounds of silence. Eur Heart J 2022; 43:2998. [PMID: 35766152 DOI: 10.1093/eurheartj/ehac340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Mario Gaudino
- Department of Cardiothoracic Surgery, Cornell Medicine, New York, NY, USA
| | - Michael E Farkouh
- Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, ON, Canada
| | - Gregg W Stone
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA
| |
Collapse
|
42
|
Madan M, Abbott JD, Lennon R, So DYF, MacDougall AM, McLaughlin MA, Murthy V, Saw J, Rihal C, Farkouh ME, Pereira NL, Goodman SG. Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial. J Am Heart Assoc 2022; 11:e024709. [PMID: 35699175 PMCID: PMC9238632 DOI: 10.1161/jaha.121.024709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background TAILOR-PCI (Tailored Antiplatelet Initiation to Lessen Outcomes due to decreased Clopidogrel Response After Percutaneous Coronary Intervention) studied genotype-guided selection of antiplatelet therapy after percutaneous coronary intervention versus conventional therapy with clopidogrel. The presence of CYP2C19 loss-of-function alleles in patients treated with clopidogrel may be associated with increased risk for ischemic events. We report a prespecified sex-specific analysis of genotyping and associated cardiovascular outcomes from this study. Methods and Results Associations between sex and major adverse cardiac events (MACE: cardiovascular death, myocardial infarction, stroke, stent thrombosis, and severe recurrent ischemia) and Bleeding Academic Research Consortium (BARC) bleeding at 12 months were analyzed using Cox proportional-hazards models. Among 5276 randomized patients, loss-of-function carriers were observed in ≈36% of both sexes, and >80% of carriers were heterozygotes. At 12 months, after adjustment for baseline differences, risks of MACE (HR , 1.28 [0.97 to 1.68]; P=0.088) and BARC bleeding (hazard ratio [HR], 1.36 [0.91 to 2.05]; P=0.14) were comparable among women and men. There were no significant interactions between sex and treatment strategy for MACE interaction P value (Pint=0.59) or BARC bleeding (Pint=0.47) nor for sex and genotype (MACE Pint=0.15, and BARC bleeding Pint=0.60). Conclusions CYP2C19 loss-of-function alleles were present in ≈1 in 3 women and men. Women had similar adjusted risks of MACE and bleeding as men following percutaneous coronary intervention. Genotype-guided therapy did not significantly reduce the risk of MACE or bleeding relative to conventional therapy for both sexes. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01742117.
Collapse
Affiliation(s)
- Mina Madan
- Schulich Heart CentreSunnybrook Health Sciences CentreUniversity of Toronto Toronto Ontario Canada
| | - J Dawn Abbott
- Division of Cardiology Lifespan Cardiovascular Institute Warren Alpert Medical School of Brown University Providence RI
| | - Ryan Lennon
- Department of Quantitative Health Sciences Mayo Clinic Rochester MN
| | - Derek Y F So
- University of Ottawa Heart Institute Ottawa Ontario Canada
| | | | | | | | - Jacqueline Saw
- Vancouver General HospitalUniversity of British Columbia Vancouver British Columbia Canada
| | - Charanjit Rihal
- Department of Cardiovascular Medicine Mayo Clinic Rochester MN
| | - Michael E Farkouh
- Peter Munk Cardiac CentreUniversity of Toronto Ontario Canada.,Heart and Stroke Richard Lewar CentreUniversity of Toronto Ontario Canada
| | | | - Shaun G Goodman
- St. Michael's HospitalUniversity of Toronto Ontario Canada.,Canadian VIGOUR Centre University of Alberta Edmonton Alberta Canada
| | | |
Collapse
|
43
|
Lee DS, Straus SE, Austin PC, Mohamed S, Taljaard M, Chong A, Fang J, Prasad T, Farkouh ME, Schull MJ, Mak S, Ross HJ. Corrigendum to 'Rationale and design of the comparison of outcomes and access to care for heart failure (COACH) trial: a stepped wedge cluster randomized trial' American Heart Journal 2021; 240:1-10. Am Heart J 2022; 248:177. [PMID: 35067340 DOI: 10.1016/j.ahj.2021.11.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Douglas S Lee
- ICES (formerly the Institute for Clinical Evaluative Sciences); Peter Munk Cardiac Centre of the University Health Network, Toronto, Canada; Ted Rogers Centre for Heart Research, Toronto, Canada; University of Toronto, Toronto, Canada
| | - Sharon E Straus
- University of Toronto, Toronto, Canada; Li Ka Shing Knowledge Institute and Unity Health, Toronto, Canada
| | - Peter C Austin
- ICES (formerly the Institute for Clinical Evaluative Sciences); University of Toronto, Toronto, Canada
| | - Shanas Mohamed
- Peter Munk Cardiac Centre of the University Health Network, Toronto, Canada
| | - Monica Taljaard
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
| | - Alice Chong
- ICES (formerly the Institute for Clinical Evaluative Sciences)
| | - Jiming Fang
- ICES (formerly the Institute for Clinical Evaluative Sciences)
| | - Treesa Prasad
- ICES (formerly the Institute for Clinical Evaluative Sciences)
| | - Michael E Farkouh
- Peter Munk Cardiac Centre of the University Health Network, Toronto, Canada; University of Toronto, Toronto, Canada
| | - Michael J Schull
- ICES (formerly the Institute for Clinical Evaluative Sciences); University of Toronto, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Susanna Mak
- University of Toronto, Toronto, Canada; Sinai Health, Toronto, Canada
| | - Heather J Ross
- Peter Munk Cardiac Centre of the University Health Network, Toronto, Canada; Ted Rogers Centre for Heart Research, Toronto, Canada; University of Toronto, Toronto, Canada
| |
Collapse
|
44
|
Gaudino M, Farkouh ME, Stone GW. Left main revascularization: an evidence-based reconciliation. Eur Heart J 2022; 43:2421-2424. [PMID: 35452115 DOI: 10.1093/eurheartj/ehac216] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 02/17/2022] [Accepted: 04/11/2022] [Indexed: 12/26/2022] Open
Affiliation(s)
- Mario Gaudino
- Department of Cardiothoracic Surgery, Cornell Medicine, New York, NY 10065, USA
| | - Michael E Farkouh
- Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, ON M5G 2N2, Canada
| | - Gregg W Stone
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, 1 Gustave L. Levy Place, New York, NY 10029, USA
| |
Collapse
|
45
|
Takahashi K, Serruys PW, Fuster V, Farkouh ME, Spertus JA, Cohen DJ, Park SJ, Park DW, Ahn JM, Onuma Y, Kent DM, Steyerberg EW, van Klaveren D. External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI. J Am Coll Cardiol 2022; 79:1458-1473. [PMID: 35422242 DOI: 10.1016/j.jacc.2022.01.049] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 01/20/2022] [Accepted: 01/25/2022] [Indexed: 12/23/2022]
Abstract
BACKGROUND Although randomized trials have established that coronary artery bypass grafting (CABG) is, on average, the most effective revascularization strategy compared with percutaneous coronary intervention (PCI) in patients with diabetes and multivessel disease (MVD), individual patients differ in many characteristics that can affect the benefits and harms of treatment. The FREEDOM (Future Revascularization Evaluation in Patients with Diabetes Mellitus) score was developed to predict different outcomes with CABG vs PCI on the basis of 8 patient characteristics and the smoking-treatment interaction. OBJECTIVES This study aimed to assess the ability of the 5-year major adverse cardiovascular event (MACE) model to predict treatment benefit of CABG vs PCI in the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) and BEST (Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease) trials. METHODS This study identified 702 patients with diabetes and MVD to mirror the FREEDOM participants. Discrimination was assessed by C-index, and calibration was assessed by calibration plots in the PCI and CABG arms, respectively. The ability of the FREEDOM score to predict treatment benefit of CABG vs PCI was assessed. RESULTS Overall, CABG was associated with a lower rate of 5-year MACE compared with PCI (12.4% vs 20.3%; log-rank P = 0.021) irrespective of a history of smoking (Pinteraction = 0.975). Both discrimination and calibration were helpful in the PCI arm (C-index: 0.69; slope: 0.96, intercept: -0.24), but moderate in the CABG arm (C-index: 0.61; slope: 0.61; intercept: -0.53). The FREEDOM score showed some heterogeneity of treatment benefit. CONCLUSIONS The FREEDOM score could identify some heterogeneity of treatment benefit of CABG vs PCI for 5-year MACE. Until further prospective validations are performed, these results should be taken into consideration when using the FREEDOM score in patients with diabetes and MVD. (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery [SYNTAX]; NCT00114972) (Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease [BEST]; NCT00997828) (Future Revascularization Evaluation in Patients with Diabetes Mellitus [FREEDOM]; NCT00086450).
Collapse
Affiliation(s)
- Kuniaki Takahashi
- Department of Cardiology, Amsterdam Universities Medical Centers, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Patrick W Serruys
- Department of Cardiology, National University of Ireland Galway, Galway, Ireland.
| | - Valentin Fuster
- The Zena and Michael Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
| | - Michael E Farkouh
- Peter Munk Cardiac Centre and the Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada
| | - John A Spertus
- Department of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; Department of Cardiology, University of Missouri-Kansas City, Kansas City, Missouri, USA
| | - David J Cohen
- Cardiovascular Research Foundation, New York, New York, USA; St. Francis Hospital and Heart Center, Roslyn, New York, USA
| | | | - Duk-Woo Park
- Department of Cardiology, Asan Medical Center, Seoul, Korea
| | - Jung-Min Ahn
- Department of Cardiology, Asan Medical Center, Seoul, Korea
| | - Yoshinobu Onuma
- Department of Cardiology, National University of Ireland Galway, Galway, Ireland
| | - David M Kent
- Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
| | - Ewout W Steyerberg
- Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, the Netherlands
| | - David van Klaveren
- Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands
| | | |
Collapse
|
46
|
Ruel M, Williams A, Ouzounian M, Sun L, Légaré JF, Poirier P, Malas T, Farkouh ME, Chedrawy E, Hassan A, Higgins J, Connelly K, McClure RS, Bewick D, Whitlock R, Graham M, Arora RC. Missing the Goal with the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Can J Cardiol 2022; 38:705-708. [PMID: 35341903 DOI: 10.1016/j.cjca.2022.03.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 03/13/2022] [Accepted: 03/20/2022] [Indexed: 11/26/2022] Open
Affiliation(s)
- Marc Ruel
- Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, ON.
| | - Anne Williams
- Division of Cardiology, Department of Medicine, Memorial University, St. John's, NL
| | - Maral Ouzounian
- Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, University Health Network, University of Toronto, ON
| | - Louise Sun
- Division of Cardiac Anesthesiology, University of Ottawa Heart Institute, Ottawa, ON
| | | | - Paul Poirier
- Faculté de pharmacie, Université Laval, Institut universitaire de cardiologie et de pneumologie de Québec, QC
| | - Tarek Malas
- Département de Chirurgie, Université Laval, Institut universitaire de cardiologie et de pneumologie de Québec, QC
| | - Michael E Farkouh
- Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre, University of Toronto, ON
| | - Edgar Chedrawy
- Division of Cardiac Surgery, QEII Health Sciences Centre, Halifax, NS
| | - Ansar Hassan
- Department of Cardiovascular Surgery, Maine Medical Center, Portland, Maine, USA
| | - Jennifer Higgins
- Division of Cardiac Surgery, St. Mary's General Hospital, Kitchener, ON
| | - Kim Connelly
- Keenan Research Centre for Biomedical Science, UnityHealth, University of Toronto, ON
| | - R Scott McClure
- Department of Cardiac Sciences, Section of Cardiac Surgery, Libin Cardiovascular Institute, University of Calgary, AB
| | - David Bewick
- Department of Medicine, New Brunswick Heart Center, Saint John, NB
| | | | - Michelle Graham
- Department of Medicine and Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB
| | - Rakesh C Arora
- Department of Surgery, Section of Cardiac Surgery, Max Rady College of Medicine, University of Manitoba, MB
| |
Collapse
|
47
|
Dubrofsky L, Lee JF, Hajimirzarahimshirazi P, Liu H, Weisman A, Lawler PR, Farkouh ME, Udell JA, Cherney DZ. A Unique Multi- and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Description and Assessment of Outcomes. Can J Kidney Health Dis 2022; 9:20543581221081207. [PMID: 35251673 PMCID: PMC8891862 DOI: 10.1177/20543581221081207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Accepted: 01/11/2022] [Indexed: 11/16/2022] Open
Abstract
Background: Patients with diabetes and co-existing chronic kidney disease and/or cardiovascular disease have complex medical needs with multiple indications for different guideline-directed medical therapies and require high health care resource utilization. The Cardiac and Renal Endocrine Clinic (C.a.R.E. Clinic) is a multi- and interdisciplinary clinic offering a unique care model to this population to overcome barriers to optimal care. Objective: To describe the patient characteristics and clinical data of consecutive patients seen in the C.a.R.E. Clinic between 2014 and 2020, with a focus on the feasibility, strengths, and challenges of this outpatient care model. Design: Single-center retrospective cohort study. Setting: The C.a.R.E. Clinic is a multi- and interdisciplinary clinic at Toronto General Hospital in Toronto, Canada. Patients: We reviewed the charts of all 118 patients who had been referred to the C.a.R.E. Clinic with type 2 diabetes mellitus, co-existing renal disease, and/or cardiovascular disease. Measurements: Demographic data, medication data, clinic blood pressure measurements, and laboratory data were assessed at the first and last available clinic visit. Methods: Data were extracted via manual chart review of paper and electronic medical records. Results: First and last attended clinic visit data were available for descriptive analysis in 74 patients. There was a significant improvement in low-density lipoprotein (LDL) cholesterol (1.9 mmol/L vs 1.5 mmol/L, P < .01), hemoglobin A1C (7.5% vs 7.1%, P = .02), and the proportion of patients with blood pressure at target (52.7% vs 36.5%, P = .04), but not body mass index (29.7 kg/m² vs 29.6 kg/m², P = .15) between the last and first available clinic visits. There was higher uptake in evidence-based medication use including statins (93.2% vs 81.1%, P = .01), SGLT-2i (35.1% vs 4.1%, P < .01), and GLP-1 receptor agonists (13.5% vs 4.1%, P = .02), while RAAS inhibitor use was already high at baseline (81.8% vs 78.4%, P = .56). There remains a significant opportunity for therapy with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Limitations: This is a retrospective chart review lacking a control group, therefore clinical improvements cannot be causally attributed to the clinic alone. New evidence and changes to guideline-recommended therapies also contributed to practice changes during this time period. Conclusions: A multi- and interdisciplinary clinic is a feasible and potentially effective way to improve evidence-based and patient-centered care for patients with diabetes, kidney, and cardiovascular disease.
Collapse
Affiliation(s)
- Lisa Dubrofsky
- Division of Nephrology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, ON, Canada
| | - Jason F Lee
- Division of Nephrology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, ON, Canada
| | | | - Hongyan Liu
- Division of Nephrology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, ON, Canada
| | - Alanna Weisman
- Division of Endocrinology & Metabolism, Department of Medicine, University of Toronto, ON, Canada
| | - Patrick R Lawler
- Ted Rogers Centre for Heart Research, University of Toronto, ON, Canada.,Peter Munk Cardiac Centre, University Health Network, University of Toronto, ON, Canada.,University of Toronto, ON, Canada
| | - Michael E Farkouh
- Peter Munk Cardiac Centre, University Health Network, University of Toronto, ON, Canada
| | - Jacob A Udell
- Division of Cardiology, Department of Medicine, Women's College Hospital, University of Toronto, ON, Canada.,Women's College Research Institute and Cardiovascular Division, Department of Medicine, Women's College Hospital, University of Toronto, ON, Canada.,Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
| | - David Z Cherney
- Division of Nephrology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, ON, Canada
| |
Collapse
|
48
|
Farkouh ME, Stone GW, Lala A, Bagiella E, Moreno PR, Nadkarni GN, Ben-Yehuda O, Granada JF, Dressler O, Tinuoye EO, Granada C, Bustamante J, Peyra C, Godoy LC, Palacios IF, Fuster V. Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol 2022; 79:917-928. [PMID: 35241226 PMCID: PMC8884342 DOI: 10.1016/j.jacc.2021.12.023] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/12/2021] [Revised: 12/15/2021] [Accepted: 12/22/2021] [Indexed: 12/15/2022]
Abstract
Clinical, laboratory, and autopsy findings support an association between coronavirus disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is characterized by mononuclear cell reactivity and pan-endothelialitis, contributing to a high incidence of thrombosis in large and small blood vessels, both arterial and venous. Observational studies and randomized trials have investigated whether full-dose anticoagulation may improve outcomes compared with prophylactic dose heparin. Although no benefit for therapeutic heparin has been found in patients who are critically ill hospitalized with COVID-19, some studies support a possible role for therapeutic anticoagulation in patients not yet requiring intensive care unit support. We summarize the pathology, rationale, and current evidence for use of anticoagulation in patients with COVID-19 and describe the main design elements of the ongoing FREEDOM COVID-19 Anticoagulation trial, in which 3,600 hospitalized patients with COVID-19 not requiring intensive care unit level of care are being randomized to prophylactic-dose enoxaparin vs therapeutic-dose enoxaparin vs therapeutic-dose apixaban. (FREEDOM COVID-19 Anticoagulation Strategy [FREEDOM COVID]; NCT04512079)
Collapse
Affiliation(s)
- Michael E Farkouh
- Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Gregg W Stone
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; The Cardiovascular Research Foundation, New York, New York, USA
| | - Anuradha Lala
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Emilia Bagiella
- Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Pedro R Moreno
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Girish N Nadkarni
- The Hasso Plattner Institute for Digital Health at Mount Sinai, New York, New York, USA
| | - Ori Ben-Yehuda
- The Cardiovascular Research Foundation, New York, New York, USA; Columbia University Medical Center, New York, New York, USA
| | - Juan F Granada
- The Cardiovascular Research Foundation, New York, New York, USA; Columbia University Medical Center, New York, New York, USA
| | - Ovidiu Dressler
- The Cardiovascular Research Foundation, New York, New York, USA
| | - Elizabeth O Tinuoye
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Carlos Granada
- Cogent Technologies Corporation, Mahwah, New Jersey, USA
| | - Jessica Bustamante
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Carlos Peyra
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Lucas C Godoy
- Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada
| | - Igor F Palacios
- Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA
| | - Valentin Fuster
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
| |
Collapse
|
49
|
Eikelboom J, Rangarajan S, Jolly SS, Belley-Cote EP, Whitlock R, Beresh H, Lewis G, Xu L, Chan N, Bangdiwala S, Diaz R, Orlandini A, Hassany M, Tarhuni WM, Yusufali AM, Sharma SK, Konstsevaya A, Jaramillo PL, Avezum A, Dans AL, Wasserman S, Camilo F, Kazmi K, Pais P, Xavier D, Lopes RD, Berwanger O, Nkeshimana M, Harper W, Loeb M, Choudhri S, Farkouh ME, Bosch J, Anand SS, Yusuf S. The Anti-Coronavirus Therapy (ACT) trials: design, baseline characteristics, and challenges. CJC Open 2022; 4:568-576. [PMID: 35252829 PMCID: PMC8887957 DOI: 10.1016/j.cjco.2022.02.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2022] [Accepted: 02/18/2022] [Indexed: 12/14/2022] Open
Abstract
Background Effective treatments for COVID-19 are urgently needed, but conducting randomized trials during the pandemic has been challenging. Methods The Anti-Coronavirus Therapy (ACT) trials are parallel factorial international trials that aimed to enroll 3500 outpatients and 2500 inpatients with symptomatic COVID-19. The outpatient trial is evaluating colchicine vs usual care, and aspirin vs usual care. The primary outcome for the colchicine randomization is hospitalization or death, and for the aspirin randomization, it is major thrombosis, hospitalization, or death. The inpatient trial is evaluating colchicine vs usual care, and the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily vs usual care. The primary outcome for the colchicine randomization is need for high-flow oxygen, need for mechanical ventilation, or death, and for the rivaroxaban plus aspirin randomization, it is major thrombotic events, need for high-flow oxygen, need for mechanical ventilation, or death. Results At the completion of enrollment on February 10, 2022, the outpatient trial had enrolled 3917 patients, and the inpatient trial had enrolled 2611 patients. Challenges encountered included lack of preliminary data about the interventions under evaluation, uncertainties related to the expected event rates, delays in regulatory and ethics approvals, and in obtaining study interventions, as well as the changing pattern of the COVID-19 pandemic. Conclusions The ACT trials will determine the efficacy of anti-inflammatory therapy with colchicine, and antithrombotic therapy with aspirin given alone or in combination with rivaroxaban, across the spectrum of mild, moderate, and severe COVID-19. Lessons learned from the conduct of these trials will inform planning of future trials.
Collapse
Affiliation(s)
- John Eikelboom
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada.,Department of Medicine, McMaster University, Hamilton, Canada
| | - Sumathy Rangarajan
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada
| | - Sanjit S Jolly
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada.,Department of Medicine, McMaster University, Hamilton, Canada
| | - Emilie P Belley-Cote
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada.,Department of Medicine, McMaster University, Hamilton, Canada
| | - Richard Whitlock
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada.,Department of Medicine, McMaster University, Hamilton, Canada
| | - Heather Beresh
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada
| | - Gayle Lewis
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada
| | - Lizhen Xu
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada
| | - Noel Chan
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada.,Department of Medicine, McMaster University, Hamilton, Canada
| | - Shrikant Bangdiwala
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada.,Department of Medicine, McMaster University, Hamilton, Canada
| | - Rafael Diaz
- ECLA (Estudios Clínicos Latino America) ICR (Instituto Cardiovascular de Rosario, Rosario, Argentina
| | - Andres Orlandini
- ECLA (Estudios Clínicos Latino America) ICR (Instituto Cardiovascular de Rosario, Rosario, Argentina
| | - Mohamed Hassany
- National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
| | - Wadea M Tarhuni
- Dept of Medicine, University of Saskatchewan, Saskatoon , Canada.,Dept of Medicine, Western University, Clinical Skills Building London, Canada.,Windsor Cardiac Centre, Windsor, Canada
| | - A M Yusufali
- Hatta Hospital, Dubai Medical College, Dubai Health Authority, Dubai, UAE
| | | | - Anna Konstsevaya
- National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russian Federation
| | | | - Alvaro Avezum
- International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil
| | | | - Sean Wasserman
- Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.,Division of Infectious Diseases and HIV Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa
| | - Felix Camilo
- Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Ecuador
| | - Khawar Kazmi
- National Institute of Cardiovascular Diseases, Rafique Shaheed Road, Karachi, Pakistan
| | - Prem Pais
- St. John's Research Institute, Bangalore, India
| | - Denis Xavier
- St. John's Medical College, St. John's Research Institute, Bangalore, India
| | - Renato D Lopes
- Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, North Carolina, USA
| | - Otavio Berwanger
- Hospital Israelita Albert Einstein, São Paulo, Brazil.,Global Cardiovascular Coalition, Alameda Campinas, São Paulo, Brazil
| | - Menelas Nkeshimana
- Centre Hospitalier Universitaire de Kigali, Rwanda.,University of Rwanda, Dept. Of Internal Medicine, Kigali, Rwanda
| | - William Harper
- Department of Medicine, McMaster University, Hamilton, Canada
| | - Mark Loeb
- Departments of Pathology and Molecular Medicine and Health Evidence Methods, Evidence, and Impact, McMaster University. Hamilton, Canada
| | - Shurjeel Choudhri
- Bayer Inc., Medical & Scientific Affairs, Pharmaceuticals, Mississauga, Canada
| | | | - Jackie Bosch
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada.,Department of Medicine, McMaster University, Hamilton, Canada
| | - Sonia S Anand
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada.,Department of Medicine, McMaster University, Hamilton, Canada
| | - Salim Yusuf
- Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada.,Department of Medicine, McMaster University, Hamilton, Canada
| |
Collapse
|
50
|
Farkouh ME, Mathew V. Antiplatelet Therapy Post PCI: Evaluating a Personalized Medicine Approach. Trends Cardiovasc Med 2022; 33:139-140. [PMID: 35158027 DOI: 10.1016/j.tcm.2022.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Accepted: 02/07/2022] [Indexed: 11/26/2022]
|